AP806A - Tricyclic compounds having activity specific for integrins, particularly avB3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same. - Google Patents

Tricyclic compounds having activity specific for integrins, particularly avB3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same. Download PDF

Info

Publication number
AP806A
AP806A APAP/P/1998/001342A AP9801342A AP806A AP 806 A AP806 A AP 806A AP 9801342 A AP9801342 A AP 9801342A AP 806 A AP806 A AP 806A
Authority
AP
ARIPO
Prior art keywords
formula
hydrazono
benz
hexahydro
radical
Prior art date
Application number
APAP/P/1998/001342A
Other versions
AP9801342A0 (en
Inventor
Serge Bernard
Denis Carniato
Jochen Knolle
Jean-Francois Gourvest
Hans-Ulrich Stilz
Jean-Georges Teutsch
Volkmar Wehner
Sarah C Bodary
Robert Mcdowell
Thomas R Gadek
Robert M Pitti
Original Assignee
Aventis Pharma Sa
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9603437A external-priority patent/FR2746394B1/en
Application filed by Aventis Pharma Sa, Genentech Inc filed Critical Aventis Pharma Sa
Publication of AP9801342A0 publication Critical patent/AP9801342A0/en
Application granted granted Critical
Publication of AP806A publication Critical patent/AP806A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/18—Nitrogen atoms not forming part of a nitro radical with hetero atoms attached to said nitrogen atoms, except nitro radicals, e.g. hydrazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C07C281/08—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones
    • C07C281/12—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones the carbon atom being part of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/02—Thiocyanates
    • C07C331/04—Thiocyanates having sulfur atoms of thiocyanate groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/02—Thiocyanates
    • C07C331/10—Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/02—Thiocyanates
    • C07C331/12—Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/02—Thiocyanates
    • C07C331/14—Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
    • C07C337/08—Compounds containing any of the groups, e.g. thiosemicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. thiosemicarbazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/516—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of nitrogen-containing compounds to >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The subject of the invention is the products of formula (I) : in which R-1, R2, R3 / £4,R5 and G are as defined in the description, the dotted lines represent an optional second bond, as well as the addition salts with acids and bases and the esters, their preparation process and the intermediates of this process, their use as medicines and the pharmaceutical compositions containing them.

Description

New tricyclic compounds, their preparation process and the intermediates of this process, their use as medicaments and the -pharmaceutical compositions containing them.
The present invention relates to new tricyclic compounds, their preparation process and the intermediates of this process, their use as medicaments and the pharmaceutical compositions containing them.
A subj ect of the present invention is the compounds of 10 general formula (I) :
in which R-j_ represents a -C=C- [A] - [B] -CORg,
-CH=CH- [A] - [B]-CORg, - (CH2) 2 - [A] - [B] - CORg , -0- [A]- [B]-CORg,
-CH2CO-[A]-[B]-CORg group, - [A] - representing 25 - either a bivalent hydrocarbonated radical derived from a saturated or unsaturated, linear or branched structure containing 1 to 12 carbon atoms and 1 to 6 heteroatoms chosen from oxygen, nitrogen or sulphur atoms,
- or a bivalent radical derived from a saturated or 30 unsaturated, linear or branched acyclic hydrocarbon containing 1 to 12 carbon atoms, [B] representing a phenyl radical, a CH[Z] radical, or a single bond,
Z represents a hydrogen atom, one of the following groups:
(D)0_g-NRaRb, (D)0_g-NH-SO2-Rc, (D)Q_g-NH-CO2-Rc, (D)0_g-NH-CO-Rc, (D)θ_g-NH-SO2-NH-Rc, (D)θ.g-NH-CO-NH-Rc, (D)0_g-CO2-Rc, (D)θ_g-SO2-Rc, (D)0_g-CO-Rc or (D)0_g-Rc in which (D)0_g is a bivalent radical derived from a saturated
ΑΡ/Γ; 9 8 / 0 1 3 4 2
AP.00806 or unsaturated, linear or branched acyclic hydrocarbon containing 0 to 6 carbon atoms,
Ra, Rb and Rc represent a hydrogen atom, a (CH2)0_3-Ar radical in which Ar represents a carbocyclic aryl group containing 6 to 18 carbon atoms, a (CH2)Q_3-Het radical in which Het represents a radical derived from a saturated or unsaturated, aromatic or non-aromatic heterocycle containing 1 to 9 carbon atoms and 1 to 5 heteroatoms chosen from oxygen, nitrogen or sulphur atoms, a (CH2)Q_3-Alk radical in which Aik represents a radical derived from a saturated or unsaturated, linear, branched or cyclic, non-aromatic hydrocarbon, containing 1 to 12 carbon atoms, the Het, Ar and
P Aik radicals being able to be non-substituted or substituted, or also, Ra and Rb represent together with the nitrogen atom to which they are linked a saturated or unsaturated, aromatic or non-aromatic, nitrogenous heterocycle optionally containing one or more heteroatoms chosen from oxygen, , nitrogen or sulphur atoms, this radical being able to be substituted or non-substituted,
- Rg represents a hydroxyl radical, an O-Alk O-Ar, ΙίΗ2,
NH-Alk, N(Aik)2 radical or the remainder of a L or D amino acid, Aik and Ar being as defined previously and being optionally substituted or not substituted,
- R2 and R3, identical or different, represent either a lg» 25 hydrogen atom, a hydroxyl radical, an O-Alk radical or an
0-(CH2)q_3-Ar radical, Aik and Ar being as defined previously, or R2 and R3 form together with a ring of -0-(CRdRe)n- type, n being an integer from 1 to 5, Rd and Re independently of each other represent a hydrogen atom, an alkyl radical containing 1 to 6 carbon atoms, or a phenyl radical,
- R4 represents a hydrogen atom, a halogen atom, one of the following groups: hydroxyl, amino, nitro, cyano, CF3, acyl or acyloxy containing 1 to 12 carbon atoms, alkyl, alkenyl, alkynyl, alkylthio, alkoxy, alkylamino, dialkylamino, dialkylaminoalkyl, dialkylaminoalkyloxy, in which the term alkyl contains 1 to 6 carbon atoms,
- R5 represents a hydrogen atom, a hydroxyl radical, a
Ζ V £ I 0 / 8 6 ,'2/dV
AP.00806 halogen atom, an O-Alk radical or an 0-(CH2)0_3-Ar radical, Aik and Ar being as defined previously,
- G represents, either a radical of formula Gl
N — (Het’)
Rh in which Rh is a hydrogen atom or an (Aik) group as defined 10 previously and (Het') is a heterocycle of general formula:
-C (H) in which (H) forms, with the N=C-NH- unit, the remainder of a saturated or unsaturated, mono- or bicyclic, aromatic or nonaromatic heterocycle containing 1 to 9 carbon atoms and 2 to 5 heteroatoms chosen from oxygen, nitrogen and sulphur atoms, this radical being able to be substituted or non-substituted,
- or an NRaRb radical (radical G2), Ra and Rb being as defined above,
- or a (Het) radical (radical G3) as defined above,
- or an -NRh-C(=X)-NHRc radical (radical G4), in which X is a sulphur or oxygen atom or NH, Rh and Rc are as defined previously,
- or an -NRh-SO2Rc radical, (radical G5), in which Rh and Rc are as defined previously, the dotted lines represent an optional second bond, as well as the addition salts with acids and bases and the esters.
R1# R2 and R2 can be in position 8, 9 or 10 of the tricycle. By compound of formula (I) is meant all the possible geometrical isomers and stereoisomers taken individually or as a mixture.
By - [A] - group representing a bivalent radical derived from a saturated or unsaturated, linear or branched structure containing 1 to 12 carbon atoms and 1 to 6 heteroatoms chosen from oxygen, nitrogen and sulphur atoms, is meant in particular, radicals derived from the alkanes some of whose
AP/P/ 98/01342
AP.ύΰ806 carbons are replaced by oxygen or sulphur atoms, or by the following groups: C=0, SO, S02, NH, N(Alk), NH-CO, N(Alk)-CO, CO-NH, CO-N(Alk), SO2-NH, SO2-N(Alk), (Aik) being as defined above. It can therefore be the following radicals:
-ch2-ch2-o-ch2-ch2-, -ch2-ch2-n(ch3)-ch2-ch2-,
CH2-CH2-C(O)-CH2-CH2, CH2-C(O)-C(Me)2-CH2.
When -[A]- represents a bivalent radical derived from a saturated or unsaturated, linear or branched, acyclic hydrocarbon containing 1 to 12 carbon atoms, there are meant in particular the alkylene radicals of formula -(CH2)n-, in which n represents an integer comprised between 1 and 12, such as -CH2-, -CH2CH2-, -CH2CH2CH2- or -CH2CH2CH2CH2-, or the alkenylene or alkynylene radicals such as -CH=CH-CH2- or -c=c-ch2-.
When these bivalent radicals are branched, they can be radicals such as -CH(CH3)-, -C(Me)2, -CH2-C(Me>2-, -CH(Et)-, -CH(C=CH)- or -C (OCH) (Et) - .
When [B] represents a -Ph- bivalent radical, the CORg group can be in ortho, meta or para position. It is preferably found in the para position.
When (D)q_5 is a bivalent radical derived from a saturated or unsaturated, linear or branched, acyclic hydrocarbon containing 0 to 6 carbon atoms, (Ό)θ_θ chosen from the values of [A] mentioned above. By (D)θ is meant the absence of this radical which once again has a single covalent bond. (D) will preferably be a single bond or a (CH2)n group, n being an integer chosen from 1, 2 or 3.
When Ra, Rb and Rc represent a (CH2)0_3-Ar, (CH2)0-3-Het, (CH2)0_3-Alk group, (CH2)Q_3 represents either a single bond in the case of (CH2)0, or the radical -CH2-,
-(CH2)2- or -(CH2)3-.
By the term (Ar) representing a carbocyclic aryl group containing 6 to 18 carbon atoms is meant a radical derived from an aromatic cyclic hydrocarbon such as the phenyl, naphthyl, phenanthrenyl radical or a radical derived from a condensed bicyclic or tricyclic hydrocarbon containing a benzene ring such as indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl or fluorenyl. The junction occurs at the
AP/P/ 98/01342
AP . 0 0 8 0 6 level of the benzene ring. It is preferably the phenyl.
By the term (Het) representing a radical derived from a saturated or unsaturated, aromatic or non-aromatic heterocycle containing 1 to 9 carbon atoms and 1 to 5 heteroatoms chosen from oxygen, nitrogen and sulphur atoms, is meant in particular:
- monocyclic heterocyclic radicals, for example the following radicals: thienyl, furyl, pyrannyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazolyl, oxazolyl, furazannyl, pyrrolinyl, imidazolinyl, pyrazolinyl, thiazolinyl, triazolyl, tetrazolyl,
- condensed heterocyclic rings, for example benzofurannyl, —benzothienyl, benzimidazolyl, benzothiazolyl, naphtho[2,3-b]thienyl, thianthrenyl, isobenzofurannyl, chromenyl, xanthenyl, phenoxathiinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, beta-carbolinyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, indolinyl, isoindolinyl, imidazopyridyl, imidazopyrimidinyl or also the condensed polycyclic systems constituted by monocyclic heterocyclic radicals as defined such as for example furo[2,3-b]pyrrole or thieno[2,3-b]furan,
- or saturated heterocyclic radicals such as pyrrolidine, piperidine, morpholine.
This term (Het) includes furthermore the values of (Het') as defined previously.
By the term (Aik) representing a radical derived from a saturated or unsaturated, linear, branched or cyclic, nonaromatic hydrocarbon, is meant in the case of acyclic hydrocarbons the alkyl radicals such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, n-pentyl, nhexyl, 2-methyl pentyl, 2,3-dimethyl butyl, n-heptyl, 235 methylhexyl, 2,2-dimethylpentyl, 3,3-dimethyl pentyl,
3-ethylpentyl, n-octyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl,
3-methyl-3-ethylpentyl, nonyl, 2,4-dimethylheptyl or ndecyl, the alkenyl radicals such as vinyl, propenyl,
AP/P/ 9 8 / 0 1 3 42
AP.00806 isopropenyl, allyl, 2-methylallyl, butenyl or isobutenyl, or the alkynyl radicals such as ethynyl, propynyl, propargyl, butynyl or isobutynyl, and in the case of the cyclic radicals, the cycioalkyi radicals, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl.
When Ra and Rb represent together with the nitrogen atom to which they are linked a nitrogenous heterocycle, they are in particular the following saturated heterocycles: morpholine, piperidine, piperazine, pyrrolidine, or the unsaturated heterocycles such as pyrimidine, pyridine or pyrazine.
When R2, R3, R4 and R5 represent an 0-(Aik) radical containing 1 to 12 carbon atoms, they are preferably methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, allenyloxy or propargyloxy. When R2, R3, R4 and R5 represent an
0-(CH2)0_3-Ar radical they are preferably the phenylethoxy and phenylpropyloxy radicals.
When R2 and R3 form together a ring of -O-(CRdRe)n-Otype, n being an integer from 1 to 5, it is in particular the
-O-CH2-O, O-C(Me2)-O, 0-C(Ph2)-0 radicals.
R2 and R3 must each be in ortho position.
When Rg represents an O-Alk or O-Ar radical, Aik and Ar being substituted or non-substituted, it is in particular one of the following radicals: (Cj-Cg) alkoxy, (ci~ci4) aryl,
;.i 25 (C-i_-Cg) alkoxy, (Cg-C14) aryloxy, (C-^-Cg) alkylcarboxyloxy, (Ci-Cg) dialkylaminocarbonylmethoxy, (Cg-C14) aryl, (C-^-Cg) dialkyl-aminocarbonylmethoxy.
When Rg represents an NH-alk, NH(alk)2 or ΝΗ-Ar radical, it is in particular one of the following radicals: (C-j_-Cg) alkylamino, di- (C-i_-Cg) alkylamino, (c6_ci4) aryl, (C2-Cg) alkylamino, (Cg-C14) arylamino.
When Rg represents the remainder of an amino acid it can be an L or D amino acid.
The L or D amino acids can be natural or non-natural.
They are preferably α-amino acids. For example, those described in Houben-Weyl, Methoden der organischen Chemie,
Volume XV/1 and 2, Georg Thieme Verlag, Stuttgart, 1974:
Aad, Abu, yAbu, Abz, 2Abz, eAca, Ach, Acp, Adpd, Ahb, Aib,
AP/P/ 9 8/01342
AP . Ο Ο 8 Ο 6 jSAib, Ala, jSAla, AAla, Alg, All, Ama, Amt, Ape, Apm, Apr,
Arg, Asn, Asp, Asu, Aze, Azi, Bai, Bph, Can, Cit, Cys, (Cys)2, Cyta, Daad, Dab, Dadd, Dap, Dapm, Dasu, Djen, Dpa, Dtc, Fel, Gin, Glu, Gly, Guv, hAla, hArg, hCys, hGln, hGlu,
His, hlle, hLeu, hLys, hMet, hPhe, hPro, hSer, hThr, hTrp, hTyr, Hyl, Hyp, 3Hyp, He, Ise, Iva, Kyn, Lant, Lcn, Leu,
Lsg, Lys, /3Lys, Alys, Met, Mim, Min, nArg, Nle, Nva, Oly,
Orn, Pan, Pec, Pen, Phe, Phg, Pic, Pro, Apro, Pse, Pya, Pyr, Pza, Qin, Ros, Sar, Sec, Sem, Ser, Thi, jSThi, Thr, Thy, Thx,
Tia, Tie, Tly, Trp, Trta, Tyr, Val, tert-butylglycine (Tbg), Neopentylglycine (Npg), Cyclohexylglycine (Chg),
Cyclohexylalanine (Cha), 2-Thienylalanine (Thia), 2,2.J diphenylaminoacetic acid, 2-(p-tolyl) 2-phenylamino acetic acid, 2-(p-chlorophenyl) amino acetic acid, or also
2- pyrrolidine acetic acid, 1,2,3,4-tetrahydroisoguinoline 3acetic acid, decahydroisoquinoline 3-acetic acid, octahydroisoindol 2-acetic acid, decahydroquinoline 2-.acetic acid, octahydrocyclopenta [b} pyrrol 2-carboxylic acid, 220 azabicyclo [2,2,2] octan-3 - carboxylic acid, 2-azabicyclo [2,2,1] heptan-3-carboxylic acid, 2-azabicyclo [3,1,0] hexan3- carboxylic acid, 2-azaspiro [4,4] nonan-3-carboxylic acid, 2-azaspiro [4,5] decan-3-carboxylic acid, spiro (bicyclo [2,2,1] heptan)-2,3-pyrrolidin-5-carboxylic acid, spiro ) 25 (bicyclo [2,2,2] octan)-2,3-pyrrolidin-5-carboxylic acid, 2azatricyclo [4,3,0,16,9] decan-3-carboxylic acid, decahydrocyclohepta [b] pyrrol-2-carboxylic acid, decahydrocycloocta [c] pyrrol-2-carboxylic acid, octahydrocyclopenta [c] pyrrol-2-carboxylic acid, octahydroisoindol-1-carboxylic acid, 2,3,3a,4,6ahexahydrocyclopenta [b] pyrrol-2-carboxylic acid, 2,3,3a,4,5,7a-hexahydroindol-2-carboxylic acid, tetrahydrothiazol-4-carboxylic acid, isoxazolidin-3-carboxylic acid, pyrazolidin-3-carboxylic acid, hydroxypyrrolidin-2-carboxylic acid, which if appropriate, can be substituted (see the following formulae):
AP/P/ 98/01342
AP.00806
AP/P/ 98/01342
AP . ο η 8 Ο 6
The heterocyclic remainders as described above are known for example from the following Patents or Patent Applications :
US-A-4,344,949; US-A-4,374,847 ; US-A-4,350,704; EP-A-29,488;
EP-A-31,741; EP-A-46,953; EP-A-49,605; EP-A-49,658; EP-A50,800; EP-A-51,020; EP-A-52,870; EP-A-79,022; EP-A-84,164; EP-A-89,637; EP-A-90,341; EP-A-90,362; EP-A-105,102; EP-A109,020; EP-A-111,873; EP-A-271,865 and EP-A-344,682.
In addition the amino acid can be in ester or amide 10 form, such as for example, methyl ester, ethyl ester, isopropyl ester, isobutyl ester, tert-butyl ester, benzyl ester, ethylamide, semicarbazide or ω-amino (C2-Cg)alkylamide.
Finally, the functional groups of these amino acids can 15 be protected. Suitable protective groups such as urethane protective groups, carboxyl protective groups or side-chain protective groups are described by Hubbuch, Kontakte (Merck) 1979, N° 3, p. 14-23 and by Bullesbach, Kontakte (Merck) 1980, N° 1, p. 23-35.
For example, the following. can be mentioned: Aloe, Pyoc,
Fmoc, Tcboc, Z, Boc, Ddz, Bpoc, Adoc, Msc, Moc, Z(NO2), Z(Haln), Bobz, Iboc, Adpoc, Mboc, Acm, tertbutyl, Obzl,
Onbzl, Ombzl, Bzl, Mob, Pic, Trt.
When G is a radical of formula G1
-N—(Het')
I
Rh and (Het') is a heterocycle of general formula:
AP/P/ 9 8 / 0 1 3 42
-C (H) in which (H) forms, with the N=C-NH- unit, a saturated or unsaturated, mono- or bicyclic, aromatic or non-aromatic heterocycle containing 1 to 9 carbon atoms and 2 to 5 heteroatoms chosen from oxygen, nitrogen and sulphur atoms,
AP . 0 0 8 0 6 this radical being able to be substituted or non-substituted, G1 represents in particular the following heterocycles:
o
in which p represents an integer from 1 to 4.
- When G is an -NRaRb radical (called G2), Ra and Rb can be a hydrogen atom, a (CH2)0_3-Ar, (CH2)Q_3-Het or (CH2)0_3-Alk (·-<? 25 radical. The Ar, Het and Aik groups also being able to be substituted by groups as defined below.
G2 can be in particular an NH2, NH-Alk group such as NHMe, NHeT, N (Aik) 2 group such as NMe2, NEt2, NMeEt, NH-(CH2)0_
2.-Ar group such as NHPh, NHCH2Ph or NHCH2Het group such as
NHCH2-pyrrol-2-yl.
When Ra is a hydrogen atom or an (Aik) group and when Rb is a (Het') group the values of G1 are found.
When Ra and Rb form together with the nitrogen atom to which they are linked a nitrogenous heterocycle, it is in particular the heterocyclic groups as described above, these being able to be substituted or non-substituted.
- When G is a (Het) radical (radical G3) this radical being able to be substituted or non-substituted, it is in
AP/P/ 9 8 / 0 1 3 4 2
AP . ο Ο 8 Ο 6 particular the heterocycles listed above and especially the heterocycles of general formula (Het') as defined above.
When this heterocycle is connected at the level of its nitrogen atom, the values of G2 are found in which Ra and Rb form a heterocycle with the nitrogen atom that carries them.
- When G is an -NRh-C(=X)-NHRc radical (radical G4), or an NRhSO2Rc radical (radical G5), in which X is a sulphur or oxygen atom or NH, Rh and Rc are as defined previously, it is in particular one of the following groups: -NH-C(=NH)-NH2,
-NH-C(=O)-NH2 or -NH-C(=S)-NH2, -NH-C(=NH)-NHCH2-Ar such as -NH-C(=NH)-NHCH2Ph, -NH-C(=NH)-NHCH2-Het, -NH-C(=NH)., NHCH2-Het', -NH-C(=NH) -NH-Alk such as -NH-C (=NH) -NHCH^, or
-NH-SO2Ph, the Ar, Het, Het1 or Aik groups being substituted or non-substituted.
The possible substituents of the (Aik), (Ar), (Het), (Het*) or NRaRb radicals forming a heterocycle, are preferably the following radicals:
- halogen: fluorine, chlorine, bromine, iodine,
- alkyl, alkenyl, alkynyl containing 1 to 12 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, vinyl or allenyl; these radicals themselves being optionally substituted by one or more halogen atoms, for example fluorine such as trifluoromethyl,
- oxo, cyano, nitro, formyl, carboxy and carboxyalkyl .·?) 25 containing 1 to 6 carbon atoms, carboxamide,
- alkoxy containing 1 to 12 carbon atoms such as methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy,
- alkylthio containing 1 to 12 carbon atoms such as methylthio, ethylthio, propylthio, isopropylthio, butylthio,
- amino, alkylamino containing 1 to 12 carbon atoms such as methylamino or ethylamino, dialkylamino containing 2 to 24 carbon atoms such as dimethylamino, diethylamino, methylethylamino, each of these dialkylamino radicals optionally being in oxidized form,
- aminoalkyl containing 1 to 12 carbon atoms such as aminomethyl or aminoethyl,
- dialkylaminoalkyl containing 3 to 25 carbon atoms such as dimethylamino methyl or ethyl,
AP,'?' 9 8 / 0 1 3 42
AP. Ο Ο 8 Ο 6
- dialkylaminoalkyloxy containing 3 to 25 carbon atoms such as dimethylaminoethyloxy,
- optionally acylated hydroxyl containing 1 to 12 carbon atoms, for example acetoxy,
- acyl containing 1 to 12 carbon atoms such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, succinyl, pivaloyl, benzoyl optionally substituted for example by a chlorine, iodine or fluorine atom; the chloroacetyl, dichloroacetyl, trichloroacetyl, bromoacetyl or trifluoroacetyl radicals can be mentioned,
- carbocyclic or heterocyclic aryl such as phenyl, furyl, thienyl, pyridinyi or aralkyl such as benzyl, these radicals themselves being optionally substituted by halogen, alkyl, alkoxy, alkylthio, amino alkyl or dialkylamino indicated above.
Of course, one or more identical or different substituents can be present. In the case of (Het) the substituents can be at the level of the NH group or the carbon atom.
These substituents also illustrate the definition of R4 .
It is understood that when R^, R2, R3, R4, Rg , Rg, Ra, Rb, Rc contain an alkyl, aryl or heterocyclic group as defined above, they can be identical or different independently of each other.
The invention naturally extends to the salts of the compounds of formula (I), such as for example the salts formed when the compounds of formula (I) contain an amino or amino guanidine function, with the following acids: hydrochloric, hydrobromic, nitric, sulphuric, phosphoric, acetic, trifluoroacetic, formic, propionic, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, alkanesulphonic such as methane- or ethanesulphonic, arenesulphonic, such as benzene or paratoluene sulphonic and arylcarboxylic, or when the compounds of formula (I) contain an acid function, with alkali metal or alkaline-earth salts or optionally substituted ammonium salts.
The invention also extends to the esters of the
ΑΡ/Γ7 9 8/01342
AP.00806 compounds of formula (I).
In a first preferred group, a subject of the invention is the compounds of general formula (I) as defined previously, corresponding to general formula (I'):
in which R’^ represents one of the following groups:
-C=C-[A']-[B' ]-COR'g, -CH=CH-[A']-[B·]-COR'g,
- (CH2)2- [A'] - [B'] - COR'g, -0- [A'] - [B' ] -COR'g,
-CH2CO-[A']-[B]-COR'g, -[A']- representing a bivalent alkylene, alkenylene or alkynylene radical containing 1 to 6 carbon atoms, [B1] representing a CH(Z') radical or a single
0 bond,
Z' represents a hydrogen atom, one of the following groups: (CH2)0-6'NRaRb, (CH2)O_g-NH-S02-Rc, (CH2)O.g-NH-C02-Rc, (CH2)0_g-NH-CO-Rc, (CH2) O.g-NH-S02-NH-Rc, (CH2)0_g-NH-CO-NH-Rc, (CH2)0_g-CO2-Rc, (CH2)Q_g-SO2-Rc, (CH2)0_g-CO-Rc or (CH2)0_g-Rc, Ra, Rb and Rc being as defined previously, R'g represents an OH, amino or alkoxy radical containing 1 to 8 carbon atoms, optionally substituted by one or more radicals chosen from hydroxy, amino, phenyl, alkylamino or dialkylamino radicals,
R’2 and R'3 represent a hydrogen atom or a methoxy radical, and G is as defined previously, the dotted lines represent an optional second bond, as well as the addition salts with acids and bases and esters.
In a second preferred group a subject of the invention is the compounds of general formula (I) as defined previously in which Rg represents one of the following groups: -OH,
2*210/86 /d/dV
AP . ο Ο 8 Ο 6
-och3, -och2ch3, -ο-(ch2)2-οη, -o-ch2-ch-ch2oh,
OH
-Ο-(CH2)2-NH2, -ο-(CH2)2-N-(CH3)2, -NH2 or -0-(CH2)-phenyl, as well as the addition salts with acids and bases and esters .
In a third preferred group a subject of the invention is the compounds of general formula (I) as defined previously in which Rj represents an 0-(CH2)θ_gCH(Z’)-COOH or
-(CH2)q_7-CH(Z')-COOH group, as well as the addition salts with acids and bases and the esters.
In a fourth preferred group a subject of the invention is the compounds of general formula (I) as defined previously, in which (Z*) is a hydrogen atom, as well as the addition salts with acids and bases and the esters.
In a fifth preferred variant a subject of the invention is the compounds of general formula (I) as defined previously, in which (Z') is the (CH2)0_g-NH-CO2-Rc or (CH2)θ_θ-NHRb group, Rb and Rc being as defined previously, as well as the addition salts with acids and bases and the esters .
In a sixth preferred group a subject of the invention is the compounds of general formula (I) as defined previously, in which Rb and Rc represent the (CH2)0_3-Ar group, Ar being as defined previously and being able to be substituted or non- substituted, as well as the addition salts with acids and bases and the esters.
In a seventh preferred group a subject of the invention is the compounds of general formula (I) as defined previously, in which G is a G4 group of formula
-NH-C(=NH)-NHRc, Rc being as defined previously, as well as the addition salts with acids and bases and the esters.
In a eighth preferred group a subject of the invention is the compounds of general formula (I) as defined previously, in which G is a G4 group of formula
NH-C(=NH)-NH2, as well as the addition salts with acids and bases and the esters.
In an ninth preferred group a subject of the invention
CM hO <90
AP.00806 is the compounds of general formula (I) as defined previously, in which G is an -NH-Het' group as defined previously and in particular
p being an integer equal to 2, 3 or 4, these heterocycles being substituted or non-substituted, as well as the addition salts with acids and bases and the esters.
In a tenth preferred group, a subject of the invention is the compounds of general formula (I) as defined previously, in which G is the group
AP,'?,' 9 8 / 0 1 3 4 2 p being an integer equal to 2, 3 or 4, as well as the addition salts with acids and bases and the esters.
In an eleventh preferred group, a subject of the 35 invention is the compounds of formula (I) as defined previously the names of which follow:
- 4-((4-((aminoiminomethyl)hydrazono)-9,10-dimethoxy-1,
2,3,4,5,6-hexahydro-8-benz(e)azulen-yl)oxy)-butanoic acid,
AP.00806
- 5-((4-((aminoiminomethyl)hydrazono)-9,10-dimethoxy-1,
2.3.4.5.6- hexahydro-8-benz(e)azulen-yl)oxy)-pentanoic acid,
- 5-((4-((aminoiminomethyl) hydrazono)-8,10-dimethoxy-1,
2.3.4.5.6- hexahydro-9-benz(e)azulen-yl)oxy)-pentanoic acid,
- 6-((4-((aminoiminomethyl)hydrazono)-9,10-dimethoxy-1,
2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-hexanoic acid,
- 7-((4-((aminoiminomethyl) hydrazono)-9,10-dimethoxy-1,
2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-heptanoic acid,
- 5-((9,10-dimethoxy-1,2,3,4,5,6-hexahydro-4-((4,5-dihydro10 1H-imidazol-2-yl)hydrazono)-8-benz(e)azulenyl)oxy)-pentanoic acid,
- ethyl 5-((4-((aminoiminomethyl)hydrazono)-9,10-dimethoxy-1,
2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-pentanoate hydrochloride,
- 4-((4-((aminoiminomethyl)hydrazono)-8,9-dimethoxy-1,
2.3.4.5.6- hexahydro-10-benz(e)azulenyl)oxy)-butanoic acid,
- 5-((4-((aminoiminomethyl)hydrazono)-8,9-dimethoxy-1,
2.3.4.5.6- tiexahydro-10-benz (e) azulenyl) oxy) -pentanoic acid,
- 5-((4-(((amino)carbonyl)hydrazono)-9,10-dimethoxy-1,
2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)-pentanoic acid,
- 5-((4-(((amino)thiocarbonyl)hydrazono)-9,10-dimethoxy1.2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-pentanoic acid,
- 4-((4-((aminoiminomethyl)hydrazono)- 8,10-dimethoxy1.2.3.4.5.6- hexahydro-9-benz(e)azulenyl)oxy)-butanoic acid,
25 - 6-((4-((4,5-dihydro-lH-imidazol-2-yl)hydrazono)-9,10dimethoxy-1,2,3,4,5,6 -hexahydro- 8 -benz(e)azulenyl)oxy)hexanoic acid,
- 5-((4-((aminoiminomethyl)hydrazono)-9,10-dimethoxy1,2,3,4,5,6 - hexahydro - 8 - benz (e) azulenyl )oxy) - 3,3 -dimethyl-430 oxo-pentanoic acid,
- 5-((4-((4,5 - dihydro-1H-imidazol-2-yl)hydrazono)-9,10dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)-3,3dimethyl-4-oxo-pentanoic acid,
- 5-((4-((aminoiminomethyl)hydrazono)-9,10-dimethoxy35 1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)-pentanoic acid hydrochloride,
- 4-((4-((4,5-dihydro-1H-imidazol-2-yl)hydrazono)-9,10dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)AP/P/ 9 8 / 0 1 3 4 2
AP.00806
LA butanoic acid,
- 5-((8-((aminoiminomethyl)hydrazono)-6,7,8,9,10,11hexahydro-azuleno(5,6-d)-1,3-benzodioxol-4-yl)oxy)-pentanoic acid,
- 5- ((8- ((aminoiminomethyl)hydrazono)-2,2-diphenyl6, 7, 8, 9 ,10, 11-hexahydro-azuleno(4,5-e)-(1,3)-benzodioxol-4yl)oxy)-pentanoic acid,
- 4-((9,10-dimethoxy-4-((1,4,5,6-tetrahydro-2-pyrimidinyl) hydrazono)-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)10 butanoic acid,
- 2-((4-((4,5-dihydro-1H-imidazol-2-yl)hydrazono)-9,10dimethoxy-1,2,3,4,5,6-hexahydro- 8 -benz(e)azulenyl)oxy)ethanoic acid,
- 3-((4-((4,5-dihydro-lH-imidazol-2-yl)hydrazono)-9,1015 dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)propanoic acid,
- 4-((4-((4,5-dihydro-ΙΗ-imidazol-2-yl)hydrazono)1.2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-butanoic acid,
- 4-((4-((4,5-dihydro-lH-imidazol-2-yl)hydrazono)20 1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)-butanoic acid,
- 0-[4[(4,5-dihydro-1H-imidazol-2-yl)hydrazono]-9,10dimethoxy-1,2,3,4,5,6-hexahydro-8-benz[e]azulenyl]-N[(phenylmethoxy)carbonyl]-DL-homoserine,
- 0-[4[(4,5-dihydro-1H-imidazol-2-yl)hydrazono]-1,2,3,4,5,625 hexahydro-8-benz [e] azulenyl] -N- [ (phenylmethoxy) carbonyl] -DLhomoserine,
- 0-[4-[(1,2,3,4-tetrahydro 6-pyrimidinyl) hydrazono] 9,10dimethoxy 1,2,3,4,5,6-hexahydro 8-benz[e]azulenyl] N[(phenylmethoxy) carbonyl] DL-homoserine,
- (2,3-dihydroxypropyl) ester of 0-(9,10-dimethoxy
1.2.3.4.5.6- hexahydro 4-[(1,4,5,6-tetrahydro 2-pyrimidinyl) hydrazono]]-8-benz(e)azulenyl] N-[(phenylmethoxy) carbonyl] DL-homoserine,
- 0-[4-[(4,5-dihydro lH-imidazol-2-yl) hydrazono] 9,1035 dimethoxy 1,2,3,4,5,6-hexahydro 8-benz(e)azulenyl] N-[(8quinolinyl) sulphonyl] DL-homoserine,
- monohydrochloride of 0-[4-[(4,5-dihydro lH-imidazol-2-yl) hydrazono] 9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8-benz(e)'/Pz 9 8/01342
AP.00806 azulenyl] N- [ [3 - [4-(3-pyridinyl) 1H-imidazol-l-yl] propoxy] carbonyl] DL-homoserine,
- 5-[ [4- [(4,5-dihydro 4-oxo 1H-imidazol-2-yl) hydrazono]
9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8-benz(e)azulenyl] oxy] pentanoic acid,
- O-[9,10-dimethoxy 1,2,3,4,5,6-hexahydro 4-[(4,5,6,7,tetrahydro 1H-1,3-diazepin-2-yl) hydrazono] 8-benz(e)azulenyl] N-[(phenylmethoxy) carbonyl] DL-homoserine,
- 0-[9,10-dimethoxy 1,2,3,4,5,6-hexahydro 4-[(3a,4,5,6,7,7ahexahydro lH-benzimidazol-2-yl) hydrazono] 8-benz(e)azulenyl] N-[(phenylmethoxy) carbonyl] DL-homoserine.
Also a subject of the invention is a preparation process for the compounds of general formula (I) characterized in that a compound of formula (II):
in which R2 , R3, R4 and R^ are as described previously with the exception of the hydroxyl value, is subjected either to the action of a compound of formula (FI) in the presence of a base,
Hal-[A]-[B]-CORg (FI) or a compound of formula (F1 -j_) in the presence of a phosphine and of diethyl azodicarboxylate:
HO- [A] - [B]-CORg (F'J in which Hal is a halogen atom, [A] , [B] and Rg are as described previously, [B] also being able to represent the
AP.00806
-CH- group, P being a protective group of the amine
NH-P function, in order to obtain a compound of formula (Ilia):
(Ilia) or to the action of an activating group then of a compound of formula (F2) in the presence of a catalyst:
II
H-C=C- [A] -[B]-C-Rg (F2)
in order to obtain a compound of formula (Illb):
(Illb) h2n-g (F3) which compounds of formula (Ilia) or (Illb) are subjected to the action of a compound of formula (F3):
AP.ο n g ο 6 in which G is as described previously, in order to obtain the compounds of formula (IVa) and (IVb) corresponding to certain products of formula (I) :
798/01342 which are subjected, if appropriate, in a suitable order,
- to the action of a base or an acid in order to cleave the ester and to obtain the corresponding acid,
- to the action of a reducing agent suitable for partially or totally reducing the unsaturations of the Rj group,
- to the action of a hydration agent of the triple bond,
- to the action of a dealkylation agent,
- to the action of a deprotection agent of the NH-P function in beta position of CO-Rg when [B] represents the CH-NHP group,
- to the formation of the NH-SO2RC, NH-C02Rc, NHCORc,
NH-S02-NH-Rc, NH-C0-NHRc group from the corresponding amine in beta position of CORg, in order to obtain the corresponding compounds of formula (I) which are subjected if
AP.00806 appropriate to the action of an acid or a base in order to obtain the corresponding salts or to the action of an esterification agent in order to obtain the corresponding esters.
The action of the compound of formula Hal-[A]-[B]-CORg (FI) is preferably carried out in the presence of a mineral base such as potassium carbonate or sodium carbonate in the presence of an aprotic dipolar solvent such as dimethylformamide. Hal is preferably a chlorine or bromine atom.
The action of the compound of formula HO-[A]-[B]-CORg (F’l) is carried out in the presence of a phosphine such as triphenylphosphine and of an agent such as diethyl azodicarboxylate (DEAD) in an aprotic solvent such as methylene chloride.
The action of the compound of formula H-C=C-[A]-[B]-CORg (F2) is preceded by that of an activating group such as triflic anhydride of formula (CF3SO2)2O in the presence of a base such as pyridine in order to form the corresponding triflate of formula (OSO2CF3) then carried out in the presence of a palladium derivative (Pd°) such as Pd(PPh3)4.
The action of NH2-G (F3) is carried out, either without solvent, or in an alcoholic solvent such as ethanol or butanol. The synthon NH2-G is optionally used in the form of a salt such as the hydrochloride or the hydrobromide.
The saponification reaction of the ester function is carried out for example by the action of an alkaline base such as soda or potash in tetrahydrofuran or a lower alcohol such as methanol or ethanol. The ester can also be cleaved in an acid medium according to methods known by a man skilled in the art.
The reduction of the unsaturations can be carried out either totally by the action of hydrogen in the presence of a catalyst such palladium on charcoal or a rhodium catalyst such as Wilkinson's reagent or partially (alkynylene becomes alkenylene) by the action of a poisoned catalyst such as palladium on barium sulphate poisoned with pyridine or triethylamine.
The hydration reaction allowing a -CH2CO-[A]-[B]-CORg
ΑΡ/Γ7 9 8/01342
AP . Ο Ο β Ο 6 group to be obtained from -C=C- [A] - [B] -CORg is preferablycarried out by the action of water in the presence of mercury sulphate.
The dealkylation reaction allowing the products of 5 formula (I) with R2, R3, R4 or R5 representing hydroxyls to be obtained is carried out in the presence of aluminium chloride or boron tribromide.
The functionalization of NH2 in alpha position of CORg, [B] representing CH-NH2 or CH-NH2, HCI, is carried out according to standard methods known in organic chemistry.
The formation of NHS02Rc from the corresponding amine is preferably carried out by the action of RcSO2Hal in the presence of a base for example triethylamine.
The formation of NHCO2Rc from the corresponding amine is 15 preferably carried out by the action of RCOH according to the method described in J. Org. Chem., 61, 3929-3934 after having previously reacted the triphosgene in the presence of sodium bicarbonate in order to intermediately obtain the isocyanate.
The salification reactions can be carried out under the 20 usual conditions. For example, in order to salify the terminal CO2H group of R-j_, the operation is carried out in the presence of a sodium salt such as sodium carbonate or sodium or potassium acid carbonate.
Similarly, the salification of the amine or of the 25 aminoguanidine which can be represented by G, by an acid, is carried out under the usual conditions. The operation is carried out for example with hydrochloric acid, for example in an ethereal solution.
The optional esterification of the products is carried 30 out under standard conditions known to a man skilled in the art.
The operation is generally carried out by reacting the acid of formula (I) or a functional derivative with a reagent capable of introducing the ester group a non-exhaustive list of which is given above in the definition of Rg.
The products of general formulae (FI), (F'l), (F2), (F3) are known or prepared according to methods known to a man skilled in the art.
AP.T/ 9 8/01342
AP.00806
The grafting order of the- different reagents can also be reversed, namely the compound of formula (II) is subjected to the action of a compound of formula F3 in order to intermediately obtain the product of formula (IIIc):
.'•ϊ
N(IIIc)
II which is subjected to the action of a compound of formula (Fl), (F'l) or (F2) in order to obtain the corresponding products of formulae (IVa) and (IVb).
In this case, it may be necessary to provide protection of the G group of the product of formula (IIIc) then, after introduction of (Fl), (F’l) or (F2), deprotection according to the methods known to a man skilled in the art (T.W. GREENE Protective Groups in Organic Synthesis. John Wiley and Sons Inc. 1991).
The deprotection reaction of the NH-P group in beta position of CO-Rg, [B] representing the CH-NHP group, is also carried out according to methods known to a man skilled in the art, in particular when P represents the CO2tBu group, by a decarboxylation reaction such as for example by the action of hydrochloric acid.
Bone is constantly subjected to a dynamic process which includes bone resorption and bone formation. These processes are mediated via specialized cells. Bone formation is the result of the deposit of a mineral matrix by osteoblasts and bone resorption is the result of the dissolution of this bone matrix by osteoclasts. Osteoporosis is characterized by a dry loss of this bone matrix. An activated mature osteoclast resorbs bone after adherence to the bone matrix by the secretion of proteolytic enzymes, and protons inside the adherence zone, resulting in depressions or holes in the
CM *0* ho o
ί.
<
AP.00806 surface of the bone which appear at the moment when the osteoclast detaches itself from the bone.
The compounds of formula (I) as well as their pharmaceutically acceptable addition salts have useful pharmacological properties. These compounds inhibit bone resorption which is mediated via the osteoclasts.
The compounds of the invention are therefore useful in the treatment of illnesses caused by loss of bone matrix, in particular osteoporosis, malignant hypercalcemia, osteopenia due to bone metastases, periodontitis, hyperparathyroidism, periarticular erosions in rhumatoid arthritis, Paget's disease, osteopenia induced by immobilization, glucocorticoid treatments or deficiencies in male or female sex hormones.
They can also be used for the treatment of inflammatory, cancerous and cardiovascular disorders including atherosclerosis, recurrence of stenosis.
They can finally be used as angiogenesis inhibitors and therefore in the treatment of tumours, by inhibition of their neovascularization, diabetic retinopathies and nephropathies.
Recent studies have shown that the fixing of the osteoclast to the bone is mediated by receptors: the integrins.
The integrins are a superfamily of receptors mediating 25 the cell/cell and more particularly cell/matrix adherence processes, including in particular a2b/33 as a blood platelet receptor (fibrinogen) and av/?3 as a receptor of vitronectin, and of bone sialoproteins such as osteopontin and thrombospondin.
These receptors which are protein heterodimers composed of two sub units ot and β, possess fixation sites for divalent ions such as Ca2+ in particular and a recognition site for their ligand predefined by the quality of their sub units.
The οίνβ3 receptor is a transmembrane glycoprotein which is expressed in a large number of cells including endothelial cells, smooth muscle cells, osteoclasts and cancerous cells which therefore bings about a pluripotentiality of the compounds according to the invention.
AP/P/ 9 8/01342
AP . Ο Ο 8 Ο 6
The ανβ3 receptors expressed on the membrane of osteoclasts are the basis of the adherence/resorption process, contribute to the organization of the cellular cytoskeleton, and are implicated in osteoporosis (Ross et al., J. Biol. Chem., 1987, 262, 7703).
The ανβ3 receptors expressed in the cells of the smooth muscle of the aorta stimulate their migration towards the neointima, which brings about the formation of atherosclerosis and the post-angioplastic reccurrence of 10 stenosis (Brown et al, cardiovascular Res. (1994), 28, 1815).
The endothelial cells secrete growth factors which are mitogenic for the endothelium and can contribute to the formation of new blood vessels (angiogenesis). Angiogenic stimulation causes the formation of new blood vessels.
Antagonists of the integrin ov/33 can therefore bring about a regression in cancerous tumours by inducing apoptosis of the angiogenic blood vessels. (Brook et al. Cell (1994) 79,
1157). .
The natural ligands of the integrin ανβ3 all contain the RGD unit (Arg-Gly-Asp). The peptides containing this RGD unit as well as anti ανβ3 antibodies are known for their ability to inhibit the resorption of dentine, to prevent the adherence of the osteoclasts on the mineralized matrices (Horton et al. Exp. Cell. Res. (1991), 195, 368).
The peptide echistatin isolated from snake venom also containing an RGD unit is described as an inhibitor of the adherence of osteoclasts to bone, and is therefore a powerful inhibitor of bone resorption in tissues cultured in vitro (Sato et al. J. Cell. Biol. (1990), 111, 1713) and in vivo in a rat (Fisher et al. Endocrinology (1993), 132, 1441).
The compounds of formula (I) as well as their pharmaceutically acceptable addition salts and their esters may possess in particular an affinity vis-a-vis the vitronectin receptor οτνβ3 or vis-a-vis other integrins having vitronectin as ligand (ov/3l, orvjSS, a2b/?3) by inhibiting binding to their natural ligand.
This property therefore makes the compounds of the invention useful for the prevention or the treatment of
AF,'?/ 9 8 / 0 1 3 4 2
AP.00806 illnesses the underlying pathology of which is caused by the ligands or cells which interact with the vitronectin receptor.
These compounds can also possess an activity vis-a-vis 5 other integrins which interact with their ligand via the RGD tripeptide sequence, conferring them with pharmacological properties which can be used to treat pathologies associated with these receptors.
This activity vis-a-vis integrins therefore makes the 10 compounds of the invention of use in the treatment of many illnesses such as those mentioned above or in the review by Dermot Cox DN&P 8(4) May 1995, 197-205 the content of which is integrated into the present Application.
A subject of the invention is therefore the compounds of 15 formula (I) as medicaments, as well as their pharmaceutically acceptable addition salts and their esters.
Among the medicaments of the invention, there can be mentioned in particular the compounds described in the experimental part.
Among these products, a more particular subject of the invention is, as medicaments, the compounds of formula (I) listed previously.
The dosage varies according to the illness to be treated and the administration route: it can vary for example from 1 mg to 1000 mg per day for an adult by oral route.
The invention extends to the pharmaceutical compositions containing as active ingredient at least one medicament as defined above.
The compounds of formula (I) are used by digestive, parenteral or local route, for example by percutaneous route. They can be prescribed in the form of plain or sugar-coated tablets, capsules, granules, suppositories, pessaries, injectable preparations, ointments, creams, gels, microbeads, nanobeads, implants, patches, which are prepared according to .35 the usual methods.
The active ingredient or ingredients can be incorporated with excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch,
ΑΡ/Γ. 9 8/01342
AP.00806 magnesium stearate, cocoa butter, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents, preservatives.
The products of formula (II), in which the hydroxy radical hydroxy is in position 10, R2 in position 8 and R2 in position 9, represent an 0-(Aik) or 0-(CH2)q.^-At group, R4 and Rg are hydrogen atoms, are prepared according to the method described in the European Patent Application N° 0729933 and in the experimental part hereafter (Preparation 2).
The two other position isomers can be prepared in the following manner:
A compound of formula (IIA):
(IIA) is to subjected to the action of an alkylation reagent, in order obtain the compound of formula (IIB):
AP/7/9 8/0 1 3 42
(IIB) which compound of formula (IIB) is subjected:
either to the action of a protection reagent of the diols in a basic medium, in order to selectively obtain the product of formula (IIC):
O (IIC)
ΑΡ.00806 in which Ρ represents the remainder of a protection reagent of the diols, which is successively subjected to the action of a protection reagent of the phenol, a deprotection reagent of the diols, an alkylation agent then a deprotection agent of the phenol in order to obtain the compound of formula (IID) corresponding to the trisubstituted product of formula (II) with OH in position 8:
(IID) or to the successive action of a protection agent of the phenol, an alkylation agent then a deprotection agent in order to obtain the compound of formula (IIE) corresponding to the trisubstituted product of formula (II) with OH in position 9:
(IIE)
CM fO r—
O
OO
CL
By dealkylation reagent is preferably meant agents such 30 as boron tribromide or aluminium chloride.
The protection reagent of the diols which is reacted on the products of formula (IIB) can be a boron derivative such as boric acid, a trialkyl borate, for example a trimethyl or triethyl borate, or also borax.
By protection agent of the phenol is meant in particular a halide such as mesyl or tosyl chloride or bromide or also a benzylated derivative such as benzyl tosylate or mesylate.
By deprotection reagent of the diols is meant in
AP . Ο Ο 8 Ο 6
Vii*particular a strong acid such as hydrochloric acid, sulphuric acid or paratoluene sulphonic acid or also an oxidizing agent, for example hydrogen peroxide, in the case of a protection by a boron derivative.
By alkylation agent is meant any standard agent known to a man skilled in the art for alkylating the phenols. There can be mentioned for example an alkyl halide such as methyl or ethyl chloride, an alkyl sulphate such as methyl or ethyl sulphate or also diazomethane.
By deprotection agent is meant a base such as soda, potash or also sodium or potassium carbonate.
The monosubstituted products of formula (II), in which R2, R3, R4 and R5 represent a hydrogen atom, are prepared according to an analogous method to that described in the
European Patent Application N° 0729933:
(i) A compound of formula (a):
(Aik)O
(a) in which 0-(Aik) is in meta or para position of the alkylcarboxylic group, (Aik) being as defined previously, is subjected to the action of a halogenation agent in order to obtain the corresponding acyl halide, (ii) which is subjected to the action of a reagent of formula (b)
(b) in which R(I) and R(II), identical or different, represent an alkyl group containing 1 to 6 carbon atoms, or R(I) and R(II)
AP. 00 8 Ο 6 together with the nitrogen atom to which they are linked, represent a saturated or unsaturated heterocycle with 5 or 6 members optionally containing another heteroatom chosen from 0 and N, in order to obtain a compound of formula (c):
(iii) which is subjected to the action of a halogenation agent in order to obtain a compound of formula (d):
in which Hal-j_ represents a halogen atom, (iv) which is subjected to the action of a Lewis acid, in order to obtain a compound of formula (e):
eh
AP/Γ, 9 θ I 0 1 3 42 (v) which is subjected to a dealkylation reagent in order to obtain the product of formula (IIF) corresponding to the expected monosubstituted product of formula (II):
AP.00906
(IIF)
The disubstituted products of formula (II), in which R2 represents O-(Aik) or 0-(CH2)0_3-Ar, R3, R4 and R5 are hydrogen atoms and OH and R2 being in position 8, 9 or 10, are prepared according to the method as described above starting from the compound of formula (a'):
in which 0-(Aik) and R2 are in meta or para position of the alkyl carboxylic group, R2 being an 0-(Aik) or -(CH2)0_3-Ar group, which is successively subjected to reactions (i), (ii), (iii), (iv) and (v) and the products of formula (IIG) are obtained corresponding to the expected bisubstituted products of formula (II):
(IIG)
Zfr£t0/86 /d/dV
The halogenation agent which is reacted on the compound of formula (a) or (a1) is for example thionyl chloride, oxalyl chloride or any other agent known to a man skilled in the art for preparing an acid halide.
AP.00806
The reagent of formula (b) is prepared starting from cyclopentanone and a secondary amine, for example diethylamine, piperidine, piperazine or, preferably, morpholine. The operation is carried out in the presence of a strong acid catalyst, for example paratoluene sulphonic acid.
The action of the enamine of formula (b) on the acid halide is preferably carried out in the presence of a tertiary amine such as triethylamine or pyridine.
The halogenation agent which is reacted on the compound of formula (c), or its disubstituted equivalent of formula (o'), can be for example thionyl chloride, phosgene, phosphorus oxychloride or, preferably, oxalyl chloride.
The Lewis acid used for cyclizing the compound of formula (d) , or its disubstituted equivalent of formula (d') is for example aluminium chloride, titanium tetrachloride, or preferably ferric chloride, or tin tetrachloride. ,The reaction, like the preceding ones, can be carried out, for example, in a halogenated solvent such as methylene chloride, chloroform or dichloroethane.
The dealkylation reagent of the compound of formula (e), or its disubstituted equivalent of formula (e*) in order to obtain the corresponding phenols is preferably aluminium chloride or boron tribromide.
The products of formula (II) in which R4 is different from the hydrogen atom are prepared by standard methods of aromatic electrophilic and nucleophilic substitution known to a man skilled in the art.
The products of formula (II) in which R5 is different from the hydrogen atom are prepared according to methods known to a man skilled in the art and in particular according to the method described in the European Patent Application N° 0729933, that is to say by halogenation then the action of water or a suitable alcohol.
The products of formula (II) in which R5 is a hydrogen atom and in which there is a double bond in position 1-2 are prepared according to methods known to a man skilled in the
AP . Ο Ο 8 Ο 6 art and. in particular according to the method described in the European Patent Application N° 0729933, that is to say by dehydration or dealkoxylation in anhydrous acid medium.
The products of formula (II) in which the junction 5 between the ring in position 5 and the ring in position 7 is saturated are prepared according to standard hydrogenation methods in particular in the presence of palladium on charcoal of the corresponding double bond.
The introduction of R4, Rg as well as the hydrogenation reaction is preferably carried out on the compounds of formula (IIA) , (IID) , (HE) , (IIF) or (IIG) .
The products of formula (II) in which R2 and Rg, each in ortho position, form a ring of -0-(CRdRe)n-0 type as defined previously, are also prepared according to methods known to a man skilled in the art and in particular according to the method described hereafter in the experimental part.
A subject of the invention is also, as intermediate products, the products of formulae (Ilia) , (IHb) , (IIIc) and (II), it being understood that the compounds of formula (lie) and the following compounds:
- 2,3,5,6-tetrahydro-9,10-dimethoxy-8-hydroxy-benz[e]azulen -41H)-one, and
2,3,5,6-tetrahydro-8,9-dimethoxy-10-hydroxy-benz[e]azulen25 4(IH)-one, are excluded. The preparation of these 2 compounds appears hereafter in the experimental part.
The following examples illustrate the invention without however limiting it.
0 PREPARATION 1: 2,3,5,6- tetrahydro- 8,9,10- trihydroxy-benz[e]azulen-4(IH)-one
Stage A: 3,4,5-trimethoxy-benzenepropanoic acid
6.8 g of potassium carbonate is added to a solution of
21.44 g of 3,4,5 -trimethoxyphenylpropenoic acid and 45 ml of water then the medium is hydrogenated for one hour under a pressure of 1200-1300 mbars in the presence of 1.8 g activated charcoal with 10% palladium, in this way 2.1 1 of hydrogen is absorbed. The reaction medium is filtered,
2^210/86 Zd.'dV
AP . 0 0 8 0 6 followed by washing with water and acidifying with 50 ml of hydrochloric acid (2N). After separation, the residue is washed with water and dried under reduced pressure at ambient temperature. In this way 19.8 g of the expected product is 5 obtained (M.P. = 1O2-1O3°C) .
IR Spectrum (CHC13)
Carbonyl: {1712 cm'1 (max) {1740 cm-1 (sh)
NMR Spectrum (CDC13)
2.69 t)} =C-CH2-CH2-CO 2.91(t)} |
6.43 (s) aromatic 2H’s 10.50 (m) mobile IH
Stage B: 3,4,5-trimethoxy-benzenepropanoyl chloride
A solution of 6 g of the product obtained in Stage A in ml of methylene chloride is dried with 1.5 g of magnesium sulphate, after filtration the reaction medium is cooled down to 5°C and 2.2 ml of thionyl chloride is added then the solution is agitated for 20 hours at ambient temperature. It is evaporated to dryness under reduced pressure by proceeding with two entrainments with cyclohexane and in this way 6.46 g of the sought product is collected. (M.P. = 60°C) . Stage C: 2 - [3 -(3,4,5 - trimethoxyphenyl) -1-oxopropyl]- cyclopentanone
A solution of 4.27 g of the product obtained in Stage B in 15 ml of methylene chloride is added over one hour 30 minutes at +5°C to a solution, cooled down to 5°C, of 2.4 ml of 1-(N-morpholinyl)cyclopentene obtained as described hereafter, 2.31 ml of triethylamine and 15 ml of methylene chloride. The reaction medium is agitated for one hour at +5°C then while allowing the temperature to rise 10 ml of 2N hydrochloric acid is added, followed by agitation for hour at ambient temperature, decanting, washing with water then with a saturated solution of sodium bicarbonate, drying, filtering and evaporating to dryness under reduced pressure. 5 g of the expected product is obtained. The crude product is purified by dissolution in 10 volumes of ethyl acetate, extracted with an N soda solution, the alkaline phase is aromatic :
3.83(s) } 3.85 (s) } {1592 cm1 {1510 cm1
H3CO-CΖ V £ I 0 / 8 6 Ad/tJV
AP . Ο Ο 8 Ο 6 washed with ethyl acetate, acidification is carried out to pH 1 with concentrated hydrochloric acid, followed by extraction with methylene chloride, drying and evaporating to dryness under reduced pressure. 2.75 g of purified product is collected.
IR Spectrum (CHCI3):
Carbonyl: {1741 cm-1 {1709 cm'1 {1658 cm'1 {-1610 cm'1
NMR Spectrum (CDCI3)
6.41 (s) arom. 2H (integration base)
3.81(s) 3.82(s)} 9H in all 3.83 (s) 3.85 (s)} 4 types of CH3O-C= aromatic: {1592 cm'1 {1509 cm'1 with OH in chelated form
Carbonyl 10 + C=C
1.86(m) CH2-CH2-CH2 -1.5H
1.95 to 2.95 (m) -7.5H in all of which =C-CH2 of several types
3.26(t) -0.4H CO-CH-CH2
CO
11.2 (wide m) mobile H
Preparation of 1-(N-morpholinvl)-cvclopentene used in
Stage C:
A solution of 100 ml of cyclohexane, 20 ml of cyclopentanone, 50 ml of morpholine and 100 mg of paratoluene sulphonic acid is agitated for 4 hours 30 minutes under reflux, eliminating the water formed. After evaporation of the solvent under reduced pressure, distillation is carried out under 12-13 mbars of pressure and 27.44 g of sought product is collected (B.p. = 83°C) .
Stage D: 1-(2-chloro-1-cyclopenten-l-yl)-3-(3,4,5-trimethoxyphenyl) -propan-1-one ml of oxalyl chloride is added at ambient temperature to a solution of 23 g of product obtained in Stage C and
230 ml of chloroform. The reaction medium is agitated for three hours at ambient temperature, and concentrated under reduced pressure by proceeding with two entrainments with
AP/P/ 9 8 / 0 1 3 42
AP. Ο 0 8 Ο 6 cyclohexane. 28 g of crude product is obtained which is recrystallized from a mixture of 50 ml of cyclohexane and 50 ml of diisopropyl ether after partial concentration. The crystals are separated out, washed with diisopropyl ether and dried under pressure. 16.24 g of the expected product is obtained. (M.P. = 93°C) .
IR Spectrum (CHC13) :
1659 cm 1599 cm'1 10 1586 cm1:
Carbonyl
1508 cm'1 NMR Spectrum
C=C + aromatic
CDC11.93 (m) : central CH2
2.69 (m)-2.81 (m) : C-CH2-C= of the cyclopentene
2.85 (t,j=7.5) - 3.08 (t,j=7.5): the other =C-CH2-C's 2.44: CH3-C=
3.68-3.81: the OCH3's
6.59- 6.68 (d,j=2) : the meta coupled aromatic CH='s 7.31-7.80(d,j=8): the aromatics.
Stage E: 2,3,5,6-tetrahydro-8,9,10-trimethoxy-benz[e]azulen4(IH)-one
900 mg of the product obtained in Stage D, 9 ml of 1,2-dichloroethane and 0.9 ml of stannic chloride are agitated for 20 hours at ambient temperature. 9 ml of water and ice is then added and the mixture is decanted, washed with water, reextraction is carried out once with methylene chloride, followed by drying over magnesium sulphate, filtration and evaporation to dryness under reduced pressure, to obtain 1 g the expected (crude) product which is purified by chromatography on silica, eluting with cyclohexane with 10% ethyl acetate, then with 25% ethyl acetate. After concentration, 700 mg of product is collected which is crystallized from 5 ml of n-hexane, followed by cooling down to 0°C, separation, washing with the minimum amount of n35 hexane, and drying under reduced pressure at ambient temperature in order to obtain 630 mg of expected product. (M.P. = 101-102°C) .
NMR Spectrum (CDC13)
CM
NO ¢30 σ>
CL <
AP. Ο Ο 8 Ο 6
1.86 (m) 2.65(dd) 2.72(t)
2.84(dd) the central CH2 2H}
2H} the other CH2's 2H}
3.84}
3.86} the OMe's 3.90}
3.06 2H}
6.59 (s) aromatic H
Stage F: 2,3,5,6-tetrahydro-8,9,10-trihydroxy-benz[e]azulen4(IH)-one
By operating as in Stage B of Preparation la, the expected demethylated product is obtained.
PREPARATION la: 2,3,5,6- tetrahydro- 8,9,10- trihydroxy-benz[e]azulen-4(IH)-one
Stage A: 2,3,5,6-tetrahydro-8,9,10-trimethoxy-benz[e]azulen-4(IH)-one
60 g of the product obtained in Preparation 2, 600 ml of
1.2- dichloroethane, 342 ml of 2N soda, 1.2 g of tetrabutylammonium bromide and 33 ml of dimethyl sulphate are agitated for 2 hours 30 minutes at 20°C. 39 ml of triethylamine is then introduced in order to destroy the excess dimethyl sulphate and agitation is carried out for one hour at 20°C ± 2°C. 342 ml of demineralized water is added, followed by agitation for 15 minutes at 20°C ± 2°C, and decanting, the aqueous phase is reextracted twice with 120 ml of
1.2- dichloroethane each time. The l,2-dichloroethane phases are combined and washed with 4 x 240 ml of demineralized water, then with 1 x 300 ml of N hydrochloric acid, then with 3 x 240 ml of demineralized water (until neutrality is obtained). The combined organic phases are dried over sodium sulphate, filtered and concentrated under ordinary pressure at 83°C to a residual volume of 480 ml.
Stage B: 2,3,5,6-tetrahydro -8,9,10-trihydroxy-benz[e]azulen4(IH)-one
480 ml of the solution obtained in (A) is heated under reflux for one hour with 102.3 g of anhydrous aluminium chloride. The medium is cooled down to 0°C ± 2°C then a mixture of 600 ml of demineralized water and 192 ml of pure sulphuric acid (concentrated) cooled down beforehand to about
0°C is added over two hours while maintaining the temperature
AP/P/ 9 8 / 0 1 3 42
AP .00806 of the reaction medium below 20°C. 3 00 ml of demineralized water is introduced over 5 minutes at 20°C ± 2°C and agitation is carried out for 16 hours at 20°C ± 2°C, followed by separation, washing twice with 60 ml of 1,2-dichloroethane each time, then with demineralized water, drying under reduced pressure, and 52.2 g of the sought product is obtained.
PREPARATION· 2: 8,9-dimethoxy-10-hydroxy-2,3,5,6-tetrahydrobenz[e]azulen-4(1Ξ)-one
Stage A: 3,4-dimethoxy 5-[[(4-methylphenyl) - sulphonyl]oxy]benzenepropanoic acid
The operation is carried out as in Stage A of Preparation 1 using 29.76 g of 3,4-dimethoxy-5[[[(4-methylphenyl)-sulphonyl]oxy]phenyl]-cinnamic acid the 15 preparation of which is given hereafter, 43.5 g of potassium carbonate, 60 ml of methanol and 1.48 g of activated charcoal with 10% palladium. In this way 28.23 g of the sought product is obtained in the form of colourless crystals (M.P. = 48-149°C) .
UV Spectrum (EtOH)
For M = 380.4 max 226nm e = 22100 infl 263nm e = 2000 infl 269nm e = 2400 max 274nm e = 2800 infl 279nm e = 2500 infl 307nm e = 450
NMR Spectrum (CDC13)
2.45(s) CH361(m) =C-CH2-CH2-C= (m)
61(d,j=2)
AP/P/ 98/01342
6.65(d,j=2) H4 Ηθ
3.68 (s) 2 CH3O-C= 3.81 (S)
7.32 (wd) H3 H5 7.80 (wd) H2 Hg
Stage B: 3,4-dimethoxy 5-[[(4-methylphenyl)-sulphonyl]oxy]35 benzenepropanoyl chloride
The operation is carried out as in Stage B of
Preparation 1 using 1.9 g of the product obtained in Stage A,
9.5 ml of methylene chloride and 0.7 ml of thionyl chloride.
AP . 0 0 8 0 6
2.24 g of the sought product is obtained, used as it is for the following stage.
Stage C: 2-[3-[3,4-dimethoxy-5-[[(4-methyIphenyl) sulphonyl]oxy]-phenyl]-1-oxopropyl]-cyclopentanone
The operation is carried out as in Stage C of
Preparation 1 starting with 2.24 g of the acid chloride obtained in Stage B and using 770 mg of 1-(N-morpholinyl) -cyclopentene (prepared in Stage C of Preparation 1), 6 ml of methylene chloride and 0.77 ml of triethylamine. After recrystallization from diisopropyl ether, 1.27 g of the sought product is obtained (M.P. = 84”C) .
IR Spectrum (CHCI3)
Carbonyl: {1742 cm'1 O-SO2 {1374 cm'1 {1709 cm'1 1178 cm'1 1658 cm'1
C=C + aromatic {1608 cm'1 1599 cm'1 1586 cm'1 1508 cm'1 NMR Spectrum (CDC13)
2.44(s) CH3-0
3.67 (s) , } 2 OCH3
3.79(s) 3.81(s)}
6.59 to 6.65 (m) arom. 2H in ortho position of the 0's.
7.32(wd) H3 H5
7.89(wd) H2 Hg
13.58(wide m) enol form OH
P/P/ 9 8 / 0 1 3 42
1.8 to 3.4 (m) 10 to 11 H other protons
UV Spectrum
- EtOH (+ dioxane) for M = 446.52 max 225nm e = 23000 max 282nm e = 7900 infl 270, 277, 290, 300, 313 nm
2 - EtOH (0.1N NaOH) max 310 nm e = 21600 infl 268, 272, 276 nm
Stage D: 1-(2-chloro-l-cyclopenten-l-yl)-3-[3,4-dimethoxy-5[ [ (4-methylphenyl) sulphonyl] oxy] -phenyl] -propan-1-one The operation is carried out as in Stage D of
Preparation 1 using 8.7 g of the product obtained in Stage C, 70 ml of chloroform and 3.5 ml of oxalyl chloride. After crystallization from diisopropyl ether, 7.75 g of the
AP. Ο Ο 8 Ο 6 sought product is obtained (M.P. = 73°C) . This product is used as it is for the following stage.
An analytical sample was obtained by recrystallization from 2.5 volumes of methylene chloride and 5 volumes of diisopropyl ether followed by concentration to 3 volumes, separation, washing with diisopropyl ether and drying under reduced pressure at ambient temperature (M.P. = 77-78°C).
IR Spectrum (CHC13)
Carbonyl: {1659 cm'
Aromatic C=C: {1599 cm-1 - 1586 cm'1 - 1508 cm'1
UV Spectrum (EtOH)
max 227nm e = 26100
infl 248nm e = 12800
inf 1 272nm e = 5300
infl 280nm e = 3200
infl 320nm
NMR Spectrum (CDC13)
1.93 (m) central -C-CH2-C- }
2.69 (m) } the C-CH2-C='s }
2.81 (m}} }
2.85(t,j=7.5)} the other =C-CH2-C's 3.08(t,j=7.5)}
2.44 CH3-C=
3.68} the OCH3's
3.81}
6.59(d,j=2) the aromatic CH's 6.68(d,j=2) meta coupled 7.31(d,j=8)}
7.80(d, j=8)}
Stage E: 8,9-dimethoxy-l0-[[(4-methylphenyl)sulphonyl]oxy]2,3,5,6-tetrahydro-benz[e]azulen-4(IH)-one
1.65 g of 98% ferric chloride is added at ambient temperature to a solution of 2.32 g of the product obtained in Stage C in 50 ml of 1,2-dichloroethane. The mixture is agitated for 48 hours at ambient temperature then poured into a mixture of water and ice, vigorous agitation is carried out for 15 minutes followed by extraction with methylene chloride, the extracts are washed with water, then with a
AP/P/ 98/01342
AP . ο ο δ Ο 6 saturated aqueous solution of sodium chloride. After drying and evaporation to dryness under reduced pressure, 2.15 g of the crude product is obtained which is chromato-graphed, eluting with cyclohexane with 50% ethyl acetate, 1.8 g of product is collected which is chromatographed again and recrystallized from a chloroform/diisopropyl ether mixture in order to obtain 720 mg of the sought product (M.P. = 138°C) . IR Spectrum (CHC13)
Carbonyl:
{1650 cm'1 {1599 cm'1 {1556 cm'1 {1512 cm1
C=C + aromatic UV Spectrum (EtOH) max 230nm e = 25300 infl 254nm e = 9400 max 323nm e - 10300
NMR Spectrum (CDC13)
1498 cm'1
-1.61(m) (2H)
-2.41 Ph-CH
20 -2.50 to 2.80
3.88(s)} the 1
3.90(s) }
6.74 H4
25 7.21(d)} c-:
7.64(d)}
Stage F: 8,9-i
ch2-c=
AP/P/ 9 8 / 0 1 3 42 [e]azulen-4(1H)-one
A mixture of 350 g of the product obtained in Stage E above, 1750 ml of methanol, 350 ml of demineralized water and 350 ml of pure caustic soda lye (concentrated) is heated under reflux for 2 hours. The reaction medium is cooled down to about 2°C ± 2°C and 467 ml of concentrated hydrochloric acid is introduced over 45 minutes while maintaining the temperature at 2°C ± 2C. 1645 ml of demineralized water is then added over 10 minutes while maintaining the temperature at 2°C ±, then the reaction medium is agitated for 30 minutes still at 2°C ± 2°C. The crystals formed are separated out,
AP . 0 0 6 0 6 washed by clarifications taking up 5 times each time with 700 ml of demineralized water at 20°C then dried at 40°C under reduced pressure in order to obtain 199.1 g of the sought product.
Preparation of 3,4-dimethoxy 5-[[(4-methylphenyl)-sulphonyl] oxy]-cinnamic acid used at the start of Preparation 2.
Stage A: methyl 3,4-dimethoxy-5 - [[(4-methylphenyl) - sulphonyl] oxy]-benzoate.
303 ml of triethylamine is added over 10 minutes at ambient temperature to an agitated mixture of 200 g of methyl gallate and 2 litres of methylene chloride. After dissolution, the reaction medium is cooled down to 0-5°C then 130 ml of dichlorodimethylsilane is added over one hour at this temperature, agitation is carried out for a further 30 minutes at this temperature. While maintaining the temperature at 0-5°C, 3 03.2 ml of triethylamine is added over 25 minutes then 227.6 g of tosyl chloride is added over 15 minutes. Agitation is continued for one hour at p-5°C, and 200 ml of acetic acid then 500 ml of demineralized water are added over 10 minutes under agitation and while allowing the temperature to rise to 20-22°C, and agitation is continued for 15 minutes at 2 0°C. The methylene chloride is distilled off at a constant volume (3.3 1) under reduced pressure replacing it with demineralized water, agitation is carried out for 2 hours at 20°C, followed by separation, washing with demineralized water, in order to obtain 523 g (damp weight) of methyl 3,4-dihydroxy-5-[[(4-methylphenyl)-sulphonyl]oxy]benzoate (methyl 3-tosylgallate). The damp product obtained is taken up in 2.17 1 de soda (2N) and 2.17 1 of methylene chloride. Agitation is carried out at 20°C until dissolution is achieved then 18 g of tetrabutylammonium bromide is added at 20°C then, over 15 minutes at 20°C, 237 ml of dimethyl sulphate is added. The reaction medium is agitated for 1.5 hours at 20-22°C. 78 ml of triethylamine is added at 20-22°C and agitation is carried out overnight at 20-22°C, followed by decanting and washing with 400 ml of demineralized water, ml of pure acetic acid is added to the organic phase, followed by agitation for 15 minutes, adding 400 ml of
AP/P/ 9 8/01342
AP . ο ο 8 Ο 6 demineralized water then decanting. The combined organic phases are concentrated to dryness, firstly under atmospheric pressure then under reduced pressure at 40 mm Hg and 60°C outside temperature. Entrainment is carried out with 5 400 ml of methanol then the dry extract obtained is taken up in 600 ml of methanol, heated under reflux until the product has totally dissolved, followed by cooling down to 0-5°C and agitation for one hour at this temperature. After separation, washing twice with 200 ml of methanol at -10°C and drying at 40°C under reduced pressure, 330.4 g of methyl
3,4-dimethoxy-5-[[(4-methylphenyl)- sulphonyl]oxy]-benzoate is thus collected. The crude product is purified by recrystallization from 330 ml of toluene. After 2 hours of agitation at -10°C, separation is carried out, followed by washing twice with 82 ml of toluene, cooling down to -15°C and drying under reduced pressure at 40°C in order to obtain 230.3 g of the purified sought product.
Stacie B: 3,4-dimethoxy 5-[[(4-methylphenyl)sulphonyl]oxy]cinnamic acid
a) 600 ml of toluene is cooled down to 0°C and 202 ml of a Vitride® solution at 70% in toluene is added at O’C and
67.6 ml of morpholine is added over one hour at 0-2°C, and the temperature is allowed to rise to 18°C. The solution thus obtained is used immediately for the following stage.
b) 200 g of methyl 3,4-dimethoxy-5-[[(4-methylphenyl)sulphonyl]oxy]-benzoate obtained in Stage A and 1400 ml of toluene are agitated for 10 minutes at 20-22°C until total dissolution is obtained. The reagent solution obtained above is added over one hour at 1O°C. Agitation is continued for one hour while allowing the temperature to rise to 18°C.
A solution cooled down to 10°C of 200 ml of concentrated sulphuric acid and 1000 ml of demineralized water is introduced over one hour at 10°C. Agitation is carried out for 16 hours at 20°C then the organic phase is decanted, washed with 5 x 200 ml of demineralized water, dried, filtered and washed with 3 x 100 ml of methylene chloride.
The intermediate aldehyde solution thus obtained is used as it is for the following stage.
AP/F/ 9 8 / 0 1 3 42
AP.0 0806
c) The intermediate aldehyde solution obtained above, 200 ml of 2-picoline, 120 g of malonic acid and 20 ml of piperidine are heated for 16 hours at 70°C + 2°C (while eliminating the methylene chloride under ordinary pressure).
The reaction medium is cooled down to 20-22°C, and while maintaining this temperature a solution of 200 ml of concentrated hydrochloric acid and 400 ml of demineralized water is added over 15 minutes. After agitation for 2 hours at 20-22°C, then cooling down to 0“C, the crystals formed are separated out, washed with demineralized water, and dried under reduced pressure at 40°C in order to obtain 171.7 g of the expected 3,4-dimethoxy 5-[[(4-methylphenyl)-sulphonyl]oxy]phenyl]-cinnamic acid.
PREPARATION 3; 9,10-dimethoxy-8-hydroxy-2,3,5,6-tetrahydro15 benz[e]azulen-4(IH)-one
Stage A: 9,10-dihydroxy- 8- [ [ (4-methylphenyl) sulphonyl] oxy] 2,3,5,6-tetrahydro-benz[e]azulen-4(IH)-one g of 2,3,5,6-tetrahydro-8,9,10-trihydroxybenz[e]azulen-4(IH)-one obtained according to Preparation 1 or la, 300 ml of tetrahydrofuran, 60 ml of triethylamine and 12.9 ml of trimethylborate are agitated for one hour 30 minutes at 20°C ± 2°C. 30 g of tosyl chloride is added and agitation is carried out for 16 hours at 20°C ± 2°C then for 10 minutes at 20°C ± 2°C, the reaction medium is poured into an agitated mixture of 900 ml of demineralized water and 150 ml of concentrated hydrochloric acid, then 90 ml of tetrahydrofuran and 60 ml of methylene chloride are added. The solution obtained is agitated for one hour at 20°C, then 150 ml of methylene chloride is introduced and agitation is continued for 15 minutes, followed by decanting and reextraction with 2 x 75 ml of methylene chloride. The combined organic phases are washed with 4 x 150 ml of demineralized water and reextracted with 75 ml of methylene chloride, after concentration under a reduced pressure of 20 mbars until distillation has stopped at 50°C, in order to obtain 47.6 g of the sought product.
Stage B: 9,10-dimethoxy-8-[[(4-methylphenyl)sulphonyl]oxy]2,3,5,6-tetrahydro-benz[e]azulen-4(IH)-one
Z V £ I 0 / 8 6 /d/dV
ΑΡ.00806
Μ,,,,μ
47.6 g of the product obtained above, 300 ml of methylene chloride, 300 ml of soda (2N), 0.6 g of tetrabutylammonium bromide and 30 ml of dimethyl sulphate are agitated for 16 hours at 20°C. 30 ml of triethylamine is then introduced in order to destroy the excess dimethyl sulphate, the reaction medium is agitated for a further hour at 20°C ± 2’C, then 150 ml of demineralized water is added, agitation is continued for 15 minutes followed by decanting. The aqueous phase is reextracted with 2 x 75 ml of methylene chloride and the combined organic phases are washed with 3 x 120 ml of demineralized water then 120 ml of N hydrochloric acid and 3 x 120 ml of demineralized water, the organic phases are combined and dried over sodium sulphate, then 120 g de silica gel (60 Mesh) is added over one hour at 20°C ± 2°C under agitation and agitation is carried out for a further one hour at 20°C, followed by filtration, washing with methylene chloride and concentrating to dryness under reduced pressure at 50°C in order to obtain 47.4 g of the sought product.
The crude product is purified by recrystallization from
390 ml of ethanol, after distillation of 90 ml of ethanol, agitation is carried out for 3 hours at 0°C ± 2°C. The residue is separated off, washed with 30 ml of ethanol at 0°C, then dried under reduced pressure at 40°C in order to obtain
41.1 g of the sought product (M.P. = 129°C) .
Stage C: 9,10-dimethoxy 8-hydroxy 2,3,5,6-tetrahydrobenz[e]azulen-4(IH)-one
4.5 g of potash then 10 ml of triethylamine are added to a suspension containing 10 g of 9,10-dimethoxy 8-(((4-methylphenyl)sulphonyl)oxy) 2,3,5,6-tetrahydro-benz30 [e]azulen-4(IH)-one obtained as in Stage B and 100 ml of methanol. The reaction medium is heated under reflux for one hour, acidified by the addition of 20 ml of acetic acid then 20 ml of water is added. Extraction is carried out with dichloromethane, the extracts are washed with water, the solvent is evaporated off at 40°C under reduced pressure and
5.7 g of expected product is collected.
PREPARATION 4; 2,3,5,6-tetrahydro-8-hydroxy-9-methoxy-benz[e] azulen-4(IH)-one and
AP/P/ 9 8/01342
AP.00806
2,3,5,6 - tetrahydro-9-hydroxy-8-methoxy-benz[e]azulen-4(1H)one
The operation is carried out in an equivalent manner to Preparation 2 Stages B, C, D, E and F but starting with 35 (3,4-dimethoxy-phenyl) propionic acid and 1.08 g of crude product is obtained containing a mixture of monohydroxylated product (8-OH/9-OMe and 9-OH/8-OMe) which is separated by chromatography on silica using a cyclohexane/ethyl acetate mixture (7/3) as eluant. In this way the following two regioisomers are obtained:
8-OH/9-OMe 0.494 g Rf (cyclohexane/ethyl acetate 6/4)=0.42 8-OMe/9-OH 0.041 g Rf (cyclohexane/ethyl acetate 6/4)=0.33 PREPARATION 5; 2,3,5,6 - tetrahydro-8-hydroxy-10-methoxy-benz [e]azulen-4(1Ξ)-one and 2,3,5,6-tetrahydro-10-hydroxy-815 methoxy-benz[e]azulen-4(1H)- one
The operation is carried out in an equivalent manner to
Preparation 2 Stages B, C, D, E and F but starting with 3-(3,5-dimethoxy-phenyl) propionic acid, and 1.428 g of a product is obtained containing a mixture of monohydroxylated products (8-OH/lO-OMe and lO-OH/8-OMe) and dihydroxylated products (8-OH/lO-OH), which are separated by chromatography on silica using a cyclohexane/ethyl acetate mixture (7/3). PREPARATION 6: 2,3,5,6- tetrahydro-9 -hydroxy-benz[e]azulen4(1H)-one
The operation is carried out in an equivalent manner to
Preparation 2 Stages B, C, D, E and F but starting with of 3-(4-methoxy-phenyl) propionic acid, and 0.448 g of expected product is obtained. Demethylation is carried out using boron tribromide.
(Rf = 0.15 cyclohexane/ethyl acetate 7/3).
PREPARATION 7; 2,3,5,6-tetrahydro-8-hydroxy-benz[e]azulen4(1H)-one
The operation is carried out in an equivalent manner to Preparation 2 Stages B, C, D, E and F but starting with
35,10.0 g of 3-(3-methoxy-phenyl propionic acid, and 2.9 g of expected product is obtained. Demethylation is carried out using boron tribromide.
(Rf = 0.15 dichloromethane/ethyl acetate 95/5).
AP/P/ 9 8 / 0 1 3 4 2
AP . Ο Ο 8 Ο 6
PREPARATION 8: Methyl ester of (DL)-4-bromo 2 -(phenylmethoxycarbonylamino) butanoic acid.
g of 2-amino 4-butyrolactone hydrobromide in 200 ml of acetic acid with 24% gaseous hydrobromic acid is agitated for 18 hours at 120°C in a closed chamber. The reaction medium is cooled down to ambient temperature, returned to atmospheric pressure, concentrated under reduced pressure, the residue is taken up in 200 ml of methanol then a current of hydrochloric acid is bubbled through for 2 hours while keeping the temperature below 35°C. The solvent is evaporated off under reduced pressure and the methyl ester of 2-amino 4bromo butanoic acid is obtained which is taken up in 250 ml of acetone and 100 ml of water, the solution is neutralized using 2N soda then 35 ml of benzyl chloroformate is slowly added. Agitation is carried out for 48 hours, followed by filtration, extraction with ethyl acetate, the solvent is evaporated off, the residue is chromatographed on silica (eluant: cyclohexane - ethyl acetate 7-3) and 27.9 g of expected product is recovered. M.p. = 90°C.
PREPARATION 9; Methyl ester of 4-bromo 2 - (terbutoxycarbonylamino) butanoic acid.
5.7 g of the methyl ester of 2-amino 4-bromo butanoic acid prepared as in Preparation 8 is agitated for 48 hours at ambient temperature in 120 ml of methanol with 24 ml of triethylamine and 9 g of diterbutyl dicarbonate. The solvents are evaporated off, the residue is taken up in water and dichloromethane, followed by filtration, extraction with dichloromethane, the solvents are evaporated off, the residue is chromatographed on silica (eluant: cyclohexane - ACOEt 30 TEA 7-3-0.5) and 1.575 g of expected product is obtained, Rf = 0.52.
PREPARATION 10: 4-(3-pyrimidinyl) 1H-imidazol 1-propanol.
505 mg of sodium ethylate is mixed with 12.5 ml of dimethylformamide, 1 g of 3-(lH-imidazol-4-yl) pyridine then
0.64 ml of chloropropanol are added and agitation is carried out for 16 hours at 55°C. The solvent is evaporated off under reduced pressure, the residue is chromatographed (eluant:
CH2Cl2-MeOH 98-2) and 1.015 g of expected product is
Z Ir £ I· 0 / 8 6 /d/dV
AP. Ο Ο 8 Ο 6 recovered.
IR Spectrum (CHC13)
OH 3626 cm-1 + associated heterocycle 1601, 1578, 1551, 1499 cm'1
PREPARATION 11: Hexahydro-2H-1,3-diazepin-2-one hydrazone.
A suspension containing 3.3 g of nitroguanidine, 7 ml of water, 3.47 g of potash and 5 g of diamine dihydrochloride is heated at 65°-70°C for one hour; 10.5 g of zinc is added, agitation is carried out for 30 minutes at ambient temperature, then 2 ml of acetic acid is added, the whole is heated for one hour at 40°C, followed by filtration and the addition of 3 g of ammonium chloride then 4 g of sodium bicarbonate. Extraction is carried out with dichloromethane, the solvent is evaporated off under reduced pressure, the residue is chromatographed on silica (eluant: C^C^-MeOHNH4OH 8-4-2) and 1.650 g of expected product is recovered. PREPARATION 12: 3a,4,5,6,7,7a-hexahydro 2-(propylthio) 1Hbenzimidazole monohydrobromide.
g of octahydro 2H-benzimidazol-2-thione and 1.3 ml of bromopropane in 20 ml of ethanol are heated under reflux until complete dissolution is obtained. The solvent is evaporated off under reduced pressure, the residue is taken up in a minimum amount of dichloromethane, isopropyl ether is added, the solvents are evaporated off under reduced pressure, the residue is recrystallized from isopropyl ether, the expected product is separated off and dried with a yield of 95%.
M.p. = 136°C.
EXAMPLE 1; 7-((4-(((amino)iminomethyl)hydrazono)-9,1030 dimethoxy-1,2,3,4,5,6-hexahydrobenz(e)azulen-8-yl)oxy)-heptanoic acid
Stage A: Methyl ester of 7-(4-oxo)-9,10-dimethoxy1,2,3,4,5,6-hexahydrobenz(e)azulen-8-yl)oxy)-heptanoic acid
A suspension containing 0.684 g of 2,3,5,6-tetrahydro-835 hydroxy-9,10-dimethoxy-benz[e]azulen-4(IH)-one (Preparation
3), 12 ml of dimethylformamide (DMF), 12 ml of tetrahydrofuran (THF), 0.7 g of potassium carbonate and 0.835 g of methyl 7-bromo oenanthate is agitated at 40°C for 4 hours.
AP/P/ 9 8 / 0 1 3 4 2
AP . Ο Ο 8 Ο 6
After evaporation under reduced pressure, the crude product is chromatographed on silica, eluting with a methylene chloride (CH2CI2)/acetone mixture (95/5). In this way 1.000 g of purified product is obtained in the form of a yellow oil.
Rf CH2Cl2/acetone 95/5: 0.5 IR (CHC13)
C=O 1732 cm'1 OMe 1438 cm'1 conjugated ketone 1641 cm'1
C=C 1592 cm'1, 1557 cm'1, 1492 cm'1 + aromatic
Stage B: Methyl ester of 7-((4-(((amino)iminomethyl)hydrazono)-9,10-dimethoxy-l,2,3,4,5,6-hexahydro-benz(e)15 azulen-8-yl)oxy)-heptanoic acid
A suspension of 0.5 g of the product of the preceding
Stage A, 5 ml of ethanol and 0.330 g of amino guanidine hydrochloride is agitated for 48 hours at ambient temperature, the solvent is evaporated off under reduced pressure and the crude product is purified by chromatography on silica, eluting with a CH2Cl2/methanol (MeOH)/ammonium hydroxide mixture (80/20/4). In this way 0.466 g of purified product is obtained in the form of a white foam.
Rf CH2Cl2/methanol (MeOH)/ammonium hydroxide 80/20/4: 0.8
IR (Nujol)
NH/NH2 3495 cm'1, 3155 cm'1 + associated C=O 1731 cm'1 C=N 1674 cm'1 C=C 1625 cm'1 aromatic 1595 cm'1 (F)
NH/NH2 1534 cm1, 1491 cm'1
Stage C: 7-((4-(((amino)iminomethyl)hydrazono)-9,10dimethoxy-l, 2,3,4,5,6-hexahydrobenz(e)azulen-8-yl)oxy)heptanoic acid
A solution containing 0.44 g of the product obtained in the preceding stage, 5 ml of ethanol and 2 ml of IN soda is agitated for 3 hours at ambient temperature, then it is neutralized with 2 ml of IN hydrochloric acid. After
2^210/86 Zd’dV
AP.00806 evaporation under reduced pressure, the crude product is purified by chromatography on silica, eluting with a CH2C12/ methanol (MeOH)/ammonium hydroxide mixture (80/20/4). In this way 0.192 g of purified product is obtained, recrystailized from methanol.
Rf CH2C12/methanol (MeOH)/ammonium hydroxide 80/20/4: 0.17 NMR (D2O + 1 drop of IN soda)
3.92 wt . 2H CH2-0
2.17 t 2H CH2-COOH
1.34 m 4H
1.55 m 2H central CH2's + CH2-C=
1.70 m 4H
2.50 tc ) 2. 90 m 8H
6.62 s IH aromatic H7
3.64 s 3H och3
3.73 s 3H och3
Mi croanalys i s
% calculated C 62.86 H 7.47 N 12.21
% found C 62.9 H 7.5 N 12.1
By operating in an equivalent manner to Example 1,
Stages A, B and C, starting with 2,3,5,6-tetrahydro-8hydroxy-9,10-dimethoxy-benz[e]azulen-4(IH)-one (Preparation 3), but with different alkylating groups and G-NH2 groups, the following products of formula (I) were prepared:
EXAMPLE 2: 4-((4-(((amino)iminomethyl)hydrazono)-9,10dimethoxy-1,2,3,4,5,6-hexahydrobenz (e) azulen-8-yl) oxy) butanoic acid
EXAMPLE 3: 4-((4-(( (amino)iminomethyl)hydrazono)-9,10dimethoxy-1,2,3,4,5,6-hexahydrobenz(e)azulen-8-yl)oxy)30 pentanoic acid
EXAMPLE 4; 5-((4-(((amino)carbonyl)hydrazono)-9,10-dimethoxy1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)-pentanoic acid EXAMPLE 5: 6-((4-(( (amino)iminomethyl)hydrazono)-9,10dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)35 hexanoic acid
EXAMPLE 6: 5-(9,10-dimethoxy-1,2,3,4,5,6-hexahydro-4-(4,5dihydro-lH-imidazolin-2-yl)hydrazono)- 8-benz(e)azulenyl)oxy)pentanoic acid
AP/P/ 9 8/01342
AP.00806
EXAMPLE 7: 5- ( (4- (( (amino)thiocarbonyl)hydrazono)-9,10dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)pentanoic acid
EXAMPLE 8? 6-(4 ((4,5-dihydro-ΙΗ-imidazolin-2-yl)hydrazono)5 9,10-dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)hexanoic acid
EXAMPLE 9: 5-((4-(((amino)iminomethyl)hydrazono)-9,10dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)-3,3dimethyl-4-oxo-pentanoic acid
EXAMPLE 10; 5 -(4((4,5-dihydro-1H-imidazolin-2-yl)hydrazono)9.10- dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)3,3-dimethyl-4-oxo-pentanoic acid
EXAMPLE 11: 4-(4((4,5-dihydro-1H-imidazolin-2-yl)hydrazono)9.10- dimethoxy-l,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)15 butanoic acid
EXAMPLE 12: 4-((9,10-dimethoxy-4- ((1,4,5,6-tetrahydro2-pyrimidinyl)hydrazono)-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)-butanoic acid
EXAMPLE 13: 2-(4((4,5-dihydro-lH-imidazolin-2-yl)hydrazono)20 9,10-dimethoxy-1,2,3,4,5,6-hexahydro- 8-benz (e)azulenyl)oxy)ethanoic acid
EXAMPLE 14; 3-(4((4,5-dihydro-lH-imidazolin-2-yl)hydrazono)9.10- dimethoxy-1,2,3,4,5,6-hexahydro- 8-benz(e)azulenyl)oxy)propanoic acid
Ζ V £ I 0 / 8 6 /d/dv
AP.00806
Ex. Starting product Alkylating product g-nh2 Rf. (1)
2 P3 Br-(CH2)3-CO2Et H2N-NH-C (=NH) -NH2 .HCI 0,12
3 P3 Br-(CH2)4-CO2Et h2n-nh-c(=nh)-nh2.hci 0,12
4 P3 Br-(CH2)3-CO2Et h2n-nh-c(=0)-NH2.HCI 0,18
5 P3 Br-(CH2)5-CO2Et H2N-NH-C(=NH)-NH2.HCI 0,17
6 P3 Br-(CH2)4-C02Et H2N-NH- c Z/ J .HBr HN 0,27
7 P3 Br-(CH2)4-C02Et h2n-nh-c(=s)-nh2.HCI 0,25
8 P3 Br-(CH2)5-CO2Et H2N-NH- / | .HBr HN 0,6
9 P3 BrCH2C(O)C(Me)2- CH2CO2Et h2n-nh-c(=nh)-nh2.HCI 0,3
10 P3 BrCH2C(O)C(Me)2CH2CO2Et H2N-NH- / 1 .HBr HN 0,5
11 P3 Br-(CH2)3-CO2Et H2N-NH- / | .HBr '' > HN 0,3
12 P3 Br-(CH2)3-CO2Et // \ H2N-NH- c \ .HBr Η K 0,63
13 P3 Br-(CH2)-CO2Et N H2N-NH- c Z/ J .HBr HN 0,3
14 P3 Br-(CH2)2-CO2Et N H2N-NH- /Z J .HBr HN 0,22
AP/P/ 9 8/01342 (1) dichloromethane/methanol/ammonium hydroxide 80/20/4
AP . Ο Ο 8 Ο 6
EXAMPLE 15: 5-((4-(((amino) iminomethyl)hydrazono)-9,10dimethoxy-1, 2,3,4,5,6-hexahydrobenz(e)azulen-8-yl)oxy)pentanoic acid hydrochloride mg of the product of Example 3 is mixed with 2 ml of 5 water and 4 1 of 0. IN hydrochloric acid then after a few minutes, the medium is lyophilized. 91 mg of expected salt is obtained.
EXAMPLE 16: 4-((4-(((amino)iminomethyl)hydrazono)-8,9dimethoxy-1,2,3,4,5,6-hexahydro-10-benz(e)azulenyl)oxy)10 butanoic acid
EXAMPLE 17: 5-((4-(((amino) iminomethyl)hydrazono)-8,9dimethoxy-1,2,3,4,5,6-hexahydro-10-benz(e)azulenyl)oxy)pentanoic acid
The operation is carried out as in Example 1 Stages A, B 15 and C, but starting with 2,3,5,6-tetrahydro-10-hydroxy-8,9dimethoxy-benz[e]azulen-4(1H)-one (Preparation 2).
Ex. Starting product Alkylating product g-nh2 Rf .
16 (II)A Br-(CH2)3-CO2Et h2n-nh-c(=nh) -nh2.hci 0,07
17 (II)A Br-(CH2)4-CO2Et H2N-NH-C(=NH)-NH2.HCI 0,07
EXAMPLE 18: 4-((4-(( (amino)iminomethyl)hydrazono)-8,10dimethoxy-1,2,3,4,5,6-hexahydro-9-benz(e)azulenyl)oxy)butanoic acid
EXAMPLE 19; 5-((4-(((amino)iminomethyl)hydrazono)-8,10dimethoxy- 1, 2 ,3,4,5,6-hexahydro-9-benz(e)azulenyl)oxy)pentanoic acid
The operation is carried out as in Example 1 Stages A, B and C, but starting with 2,3,5,6-tetrahydro-9-hydroxy-8,1030 dimethoxy-benz[e]azulen-4(1H)-one.
AP/P/ 9 8 / 0 1 3 4 2
AP . Ο Ο 8 Ο 6
Ex. Starting product Alkylating product g-nh2 Rf .
18 (II)ei Br-(CH2)3-CO2Et h2n-nh-c(=nh)-nh2.HCl 0,10
19 (Wei Br-(CH2)4-CO2Et h2n-nh-c(=nh)-nh2.HCl 0,07
EXAMPLE 20: 4- ( (4 ((4,5-dihyd.ro-lH-ixo.idazol-2-yl) hydrazono) 1,2,3,4,5,6-hexahydro-9-benz(e)azulenyl)oxy)-butanoic acid
Stage A: ethyl ester of 4-(4-oxo)-1,2,3,4,5,6-hexahydrobenz(e)azulen-9-yl)oxy)-butanoic acid
A suspension containing 0.6 g of 2,3,5,6-tetrahydro-9hydroxy-benz[e]azulen-4(IH)-one (Preparation 6), 12 ml of dimethylformamide (DMF), 12 ml of tetrahydrofuran (THF),
0.7 g of potassium carbonate and 0.7 ml of ethyl bromobutyrate is agitated at ambient temperature overnight.
After evaporation under reduced pressure the crude product is t
chromatographed on silica, eluting with a methylene chloride mixture (dichloromethane/acetone 95/5). In this way 0.608 mg of purified product is obtained in the form of a yellow oil. IR (CHC1.3)
C=O 1728 cm'1 conj. ketone 1641 cm-1
Aromatic C=C's 1610 cm-1, 1590 cm-1, 1569 cm-1, 1499 cm1 StageJB: ethyl ester of 4-((4-((4,5-dihydro-lH-imidazolin-2yl)hydrazono)-1,2,3,4,5,6-hexahydrobenz(e)azulen-9-yl)oxy)25 butanoic acid
608 mg of the product of the preceding Stage A, 10 ml of butanol and 600 mg of the following cyclic amino guanidine hydrobromide: (4,5-dihydro-lH-imidazolin-2-yl)-hydrazine, are agitated under reflux for 24 hours, the solvent is evaporated off under reduced pressure and the crude product is purified by chromatography on silica, eluting with a C^C^/methanol (MeOH)/ammonium hydroxide mixture (80/20/4). In this way 0.604 g of expected product is obtained.
IR (CHC13) =C-NH- 3451 cm'1
AP/P/ 9 8 / 0 1 3 4 2
AP.00806
C=O 1728 cm1 (ester)
C=N + C=C + aromatics: 1627 cm1 (F), 1568 cm1, 1548 cm-1, 1497 cm1, 1488 cm'1
Stage C: 7-((4,5-dihydro-1Η-imidazolin-2-yl)hydrazono)
-1,2,3,4,5,6-hexahydrohenz(e)azulen-9-yl)oxy)-butanoic acid.
A solution containing 0.604 g of the product obtained in the preceding stage, 8 ml of ethanol, 5 ml of tetrahydrofuran and 2 ml of 2N soda is agitated for 4 hours at ambient temperature, then it is neutralized with 2 ml of hydrochloric acid. After evaporation ^under reduced pressure, the crude product is purified by chromatography on silica, eluting with a dichloromethane (CH2C12)/methanol (MeOH)/ ammonium hydroxide mixture (80/20/4). In this way 0.298 g of purified product is obtained, recrystallized from methanol.
Rf (dichloromethane/methanol/ammonium hydroxide 80/20/4): 0.2
NMR (d2o + 1 drop of IN soda)
1.71 (w) 2H o-ch2-ch2-ch2-co
1.96 (m) 2H CH2 in position 2 (cyclopentene)
2.30 (t) 2H ch2-CO
2.50 to 2 :.75 8H ch2-c=
3.45 (ws) 4H ch2-n=
3.89 (wt) 2H Ph-O-CH2-C
6.70 (m) 2H H10 and Ηθ
7.00 (d, J=8) h7
AP/P/ 9 8/01342
EXAMPLE 21; 4-(4((4,5-dihydro-ΙΗ-imidazolin-2-yl)hydrazono)1.2.3.4.5.6- hexahydro-8-benz(e) azulenyl)oxy)-butanoic acid The operation is carried out as in Example 20 but starting with 0.856 g of 2,3,5,6-tetrahydro-8-hydroxybenz[e]azulen-4(IH)-one (Preparation 7) and 0.299 g of expected product is obtained.
Rf (dichloromethane/methanol/ammonium hydroxide 80/20/4):0.27 EXAMPLE 22 : 5-((8-(( (amino) iminomethyl) hydrazono) 6,7,8,9,10,11-hexahydro-azuleno(5,6-d)-1,3-benzodioxol-4-yl)oxy)-pentanoic acid
Stage A: ethyl ester of 5-(((4-oxo)-9,10-dihydroxy1.2.3.4.5.6- hexahydro-benz(e)azulen-9-yl)oxy)-pentanoic acid
1) protection
4.42 ml of trimethoxyborate and 20.4 ml of triethylamine
AP. Ο Ο 8 Ο 6
Me»»' are added to a solution, under an inert atmosphere, of 10 g of 2,3,5,6-tetrahydro-8,9,10-trihydroxy-benz[e]azulen-4(IH)one (Preparation 1) in 100 ml of tetrahydrofuran, while maintaining the temperature between 37 and 39°C, then the reaction medium is agitated at ambient temperature for 3 hours.
2) alkylation and deprotection
Next 9.7 ml of ethyl bromo-5-valerate, 100 ml of dimethylformamide and 8.4 g of potassium carbonate are added and agitation is carried out for 2 days at 60°C. The reaction mixture is then treated with 120 ml of water and 50 ml of 36N concentrated hydrochloric acid, agitation is carried out for one hour, ethyl acetate is added, the organic and aqueous phases are separated off. The organic phase is then washed, dried and evaporated under reduced pressure. A crude product is obtained which is purified by chromatography on silica, eluting with a cyclohexane/ethyl acetate mixture (70/30). 5.2 g of expected pure product is obtained.
Rf (dichloromethane/methanol 95/5) = 0.82
Rf (cyclohexane/ethyl acetate 70/30) = 0.23
Stage B: ethyl ester of 5- (((8-oxo)-6,7,8,9,10,11-hexahydroazuleno(5,6-d)-1,3-benzodioxol-4-yl)oxy))-pentanoic acid
2.5 g of the product obtained in the preceding stage, ml of dimethylformamide, 3.6 g of CsF and 1.4 ml of dibromomethane are mixed together under an inert atmosphere at 60°C for one hour. After filtration and rinsing with methanol, evaporation is carried out under reduced pressure and the crude product is purified by chromatography on silica, eluting with a cyclohexane/ethyl acetate mixture (85/15). 1.73 g of expected pure product is obtained.
(M.P. = 118°C)
Rf (cyclohexane/ethyl acetate 80/20) = 0.25
Stage C: ethyl ester of 5-((8-(((amino)iminomethyl)hydrazono)-6,7,8,9,10,11-hexahydro-azuleno(5,6-d)-1,335 benzodioxol-4-yl)oxy)-pentanoic acid
551 mg of the product obtained in the preceding stage and 467 mg of aminoguanidine hydrochloride are mixed together overnight at 12 0°C, then purification is carried out by
CM •βίο
CO cn cC
CL «X
AP.00806 chromatography, eluting with a dichloromethane/methanol/ ammonium hydroxide mixture (80/20/4) . 174 mg of the expected product is obtained.
Rf (dichloromethane/methanol/ammonium hydroxide 80/20/4) 0.98 5 Stage D: 5-( (8- ( ( (amino)iminomethyl)hydrazono)-6,7,8,9,10,11hexahydro-azuleno(5,6-d)-1,3-benzodioxol-4-yl)oxy)-pentanoic acid
274 mg of the product obtained in the preceding stage and 1.86 ml of IN soda are mixed together at ambient temperature for one hour 30 minutes, then the mixture is neutralized by a IN hydrochloric acid solution, and evaporated under reduced pressure. The crude product is purified by chromatography, eluting with a dichioromethane/ methanol/ammonium hydroxide mixture (80/20/4). 141 mg of the expected product is obtained.
Rf (dichloromethane/methanol/ammonium hydroxide 80/20/4) 0.23 NMR (DMSO)
1.55 to 1.9 (m) £H 1.55 to 1.9 (m) 2H 20 2.26 (t) 2H
2.65 to 3.00 (m) 8H 4.07 (t) 2H 5.95 (s) 2H 6.61 (m) IH 25 mobile H's (wide m) o-ch2-ch2-ch2· ch2-co
CH2 in position 2 (cyclopentene) ch2-co >wi<’ ch2-C= o-ch2-ch2•o-ch2-o
AP/P/ 9 8 / 0 1 3 4 2
NH-C(=NH)-NH2.
EXAMPLE 23: 5-((8-(((amino)iminomethyl)hydrazono)-2,2diphenyl-6,7, 8,9,10,11-hexahydro-azuleno(4,5-e)-1,3benzodioxol-4-yl)oxy)-pentanoic acid
The operation is carried out as in the preceding 30 example, starting with 374 mg of the product obtained in
Stage A of the preceding example and 0.19 ml of diphenyldichioromethane. 198 mg of expected product is obtained.
Rf (dichloromethane/methanol/ammonium hydroxide 80/20/4)= 0.17
EXAMPLE 24: 0-[4-[(4,5-dihydro-IH-imidazol-2-yl)hydrazono)9,10-dimethoxy-l,2,3,4,5, 6-hexahydro-8-benz(e)azulenyl]-N[(phenylmethoxy)carbonyl]-DL-homoserine.
Stage A: methyl ester of O-[(4-oxo)-9,10-dimethoxyAP.00806
1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl]-N-[(phenylmethoxy)carbonyl]-DL-homoserine
0.6 g of 2,3,5,6-tetrahydro-8-hydroxy-9,10-dimethoxybenz[e]azulen-4(IH)-one (Preparation 3), 10 ml of dimethyl5 formamide (DMF), 10 ml of tetrahydrofuran, 1 g of potassium carbonate and 0.867 g of methyl ester of (DL)-4-bromo-2(phenylmethoxycarbonylamino)butanoic acid prepared as indicated in preparation 8 are agitated overnight at ambient temperature. After evaporation under reduced pressure, the crude product is chromatographed on silica, eluting with a methylene chloride (CH2CI2)/acetone mixture (95/5). In this way 1.166 g of purified product is obtained in the form of a yellow oil.
IR <CHC13)
C=O 1740 cm1 (sh.), 1721 cm'1 conj . ketone 1642 cm 1
Aromatic C=C's 1593 cm1, 1559 cm1, 1508 cm'1, 1493 cm'1 Stage B: methyl ester of 0-[4-[(4,5-dihydro-IH-imidazol-2yl)hydrazono)-9,10-dimethoxy-l, 2,3,4,5,6-hexahydro-8-benz20 (e)azulenyl]-N-[(phenylmethoxy)carbonyl]-DL-homoserine
539 mg of the product of the preceding Stage A, 15 ml of butanol and 600 mg of the following cyclic amino guanidine hydrobromide: (4,5-dihydro-lH-imidazol-2-yl)-hydrazine, are agitated for 24 hours at 120C, the solvent is evaporated off under reduced pressure, and the crude product is purified by chromatography on silica, eluting with a CH2C12/methanol (MeOH)/ammonium hydroxide mixture (80/20/4). In this way 0.641 g of expected product is obtained.
IR (CHC13) =C-NH- 3451 cm1 + associated
C=0 1740 cm'1 (sh.), 1720 cm'1 (max)
C=N + C=C + aromatics + amide II: 1667 cm'1 (F),
1606 cm1, 1508 cm'1, 1490 cm'1.
Stage C: 0-[4-[(4,5-dihydro-IH-imidazol-2-yl)hydrazono)-9,1035 dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl]-N[(phenylmethoxy)carbonyl]-DL-homoserine.
A solution containing 0.6 g of the product obtained in the preceding stage, 10 ml of ethanol and 2 ml of 2N soda is
AP/P/ 9 8/01342
AP .00806 agitated for 2 hours at ambient temperature, then it is neutralized with 2 ml of hydrochloric acid. After evaporation under reduced pressure, the crude product is purified by chromatography on silica, eluting with a CH2C12/ methanol (MeOH)/ammonium hydroxide mixture (80/20/4). In this way 0.349 g of purified product is obtained, recrystailized from methanol.
Rf CH2Cl2/methanol (MeOH)/ammonium hydroxide 80/20/4: 0.37 EXAMPLE 25: O-[4-[(4,5-dihydro-1H-imidazol-2-yl)hydrazono)10 1,2,3,4,5,6-hexahydro-8-benz(e) azulenyl]-N-[(phenylmethoxy)carbonyl]-DL-homoserine.
The operation is carried out in an equivalent manner to Example 24 but starting with 0.428 g of 2,3,5,6-tetrahydro9-hydroxy-benz[e]azulen-4(1H)-one (Preparation 7). 245 mg of expected product is obtained.
Rf CH2Cl2/methanol (MeOH)/ammonium hydroxide 80/20/4: 0.5 EXAMPLE 26; 0- [4- [(1,2,3,4 -tetrahydro 6-pyrimidinyl) hydrazono] 9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8-benz[e]azulenyl] N-[(phenylmethoxy) carbonyl] DL-homoserine.
Stage A: Monohydrobromide of the methyl ester of 0-[9,10dimethoxy 1,2,3,4,5,6-hexahydro 4-[(1,4,5,6-tetrahydro 2pyrimidinyl) hydrazono] 8-benz(e)azulenyl] N-[(phenyImethoxy) carbonyl] DL-homoserine.
The operation is carried out as in Example 24 Stage B starting with 200 mg of the product obtained as in Example 24 Stage A in 2 ml of butanol and 74.5 mg of tetrahydro-2(1H)pyrimidinone hydrazone monohydrobromide and heating under reflux for 16 hours. The reaction medium is allowed to return to ambient temperature, extraction is carried out with dichloromethane, the extracts are dried, the solvent is evaporated off under reduced pressure and 152 mg of expected product is obtained.
Stage B: 0-[4-[ (1,2,3,4-tetrahydro 6-pyrimidinyl) hydrazono]
9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8-benz[e]azulenyl] N35 [(phenyImethoxy) carbonyl] DL-homoserine.
The operation is carried out as in Example 24 Stage C using 131 mg of product obtained in Stage A above in solution in 1.3 ml of ethanol and 0.43 ml of N soda. The reaction
AP/P/ 98/01342
ΑΡ.ο ο 8 ο 6 medium is neutralized by the addition of N hydrochloric acid, the solvent is evaporated off, and after filtration and drying, 78 mg of expected product is obtained. M.p. = 172°C. NMR Spectrum (CDCl-j)
ΧΪΗ*'
5 1.90 (m) (2H) CH2 in posit
2.03 (m) central CH2
2.36 (m) (2H)
2.60 to 3 .00 (8H) the =C-CH2’s
3.48 (wm) (4H) the =N-CH2’s
10 3.77 (s) 3.78 (s) (9H) the =C-OMe’s
4.01 (m) (1H) 4.17 $-o-ch2
4.67 (P) =c-ch-n-c=
5.14 (ws) CO0-CH2-4>
6.13 (d) =C-NH-CH
15 6.49 (ws) h4
«7.36 (m) (5H) Φ-C
EXAMPLE 27: (2,3-dihydroxypropyl) ester of O-(9,10-dimethoxy
1,2,3,4,5,6-hexahydro 4-[(1,4,5, 6-tetrahydro 2-pyrimidinyl) hydrazono]-8-benz(e)azulenyl] N-[(phenylmethoxy) carbonyl]
DL-homoserine.
Stage A: [(2,2-dimethyl 1,3-dioxolan-4-yl) methyl] ester of 0-[9,10-dimethoxy 1,2,3,4,5,6-hexahydro 4-((1,4,5,6tetrahydro-2-pyrimidinyl) hydrazono] 8-benz(e)azulenyl] N[(phenyl-methoxy) carbonyl] DL-homoserine.
0.3 g of product prepared as in Example 26 in 1 ml of dimethylformamide and 1 ml of dichloromethane, 96 mg of 1-(3dimethylaminopropyl) 3-ethylcarbodiimide hydrochloride and 68 mg of 1-hydroxy benzotriazole hydrate are cooled down to 0°C. The mixture is agitated for 30 minutes at ambient temperature, 0.06 ml of solketal is introduced and agitation is continued for 3 hours and 30 minutes. The reaction medium is diluted with water, extraction is carried out with dichloromethane and 0.6 g of crude product is recovered which is purified by chromatography on silica (eluant: CHCl2-MeOH
90-10). 0.352 g of expected product is obtained.
IR Spectrum (CHC13)
NH 3400 cm-1
C=0 1745 (sh), 1719 cm1
AP/P/ 9 8/01342
ΑΡ . 0 0 8 0 6
NMR Spectrum (CDC13)
1.88 (m) (2H)
15 1.98 }
2.36 }
2.60 to 3.10 (8H)
3.43 (m) (4H)
3.79 (s)
20 3.81 }
3.60 to 3.90
«=4.00 to 4.30
}
4.64 (m) (IH)
25 5.13 (s)
6.53 (s)
7.20 to 7.38
EXAMPLE 28: O-[4-[(4
C=N, C=C } aromatic, amide 11} 1672 (F), 1645, 1597, 1565 (f),
1507, 1492 cm1
Stacre B: (2,3 - dihydroxypropyl) ester of 0-(9,10-dime thoxy 5 1,2,3,4,5,6-hexahydro 4 -[(1,4,5,6 - tetrahydro 2-pyrimidinyl) hydrazono]- 8-benz(e)azulenyl] N-[(phenyImethoxy) carbonyl]
DL-homoserine.
0.320 g of product obtained in Stage A is agitated for 6 hours at ambient temperature in 3 ml of ethanol and 1 ml of
2N hydrochloric acid. After evaporation of the solvents and chromatography on silica (eluant: CH2C12-Me0H-NH40H 80-20-4), 0.112 g of expected product is obtained.
} central CH2's and CH2 in position 9 =c-ch2 =n-n-ch2 }
Φ-OMe o-ch2-ch-o } coo-ch2-ch <i>-O-CH2-CH2 =C-CH-N-C=
COO-CH2-4>
h4 the Φ-C’s
-dihydro lH-imidazol-2-yl) hydrazono]
9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8-benz(e)azulenyl] N30 [(8-quinolinyl) sulphonyl] DL-homoserine.
Stage A: Methyl ester of 0-(9,10-dimethoxy 1,2,3,4,5,6hexahydro 4-oxo 8-benz(e)azulenyl) N-[(1,1-dimethylethoxy) carbonyl] DL-homoserine.
4.1 g of product prepared as in Preparation 3 and 5 g of the ester prepared as in Preparation 9 are agitated at ambient temperature for 65 hours in 50 ml of dimethylformamide and ml of tetrahydrofuran in the presence of 5 g of potassium
AP/P/ 98/01342
AP.00806 carbonate and dimethylaminopyridine. The solvent is evaporated off under reduced pressure, the residue is purified by chromatography on silica (eluant: CH2C12 acetone 95-5) and 7.3 g of expected product is recovered.
IR Spectrum (CHCI3) =C-NH 3430 cm'1
C=O 1744 cm1 (methyl ester)
1710 cm'1 (NH-BOC)
1643 cm'1 (conjugated ketone) aromatic + amide II 1593, 1559, 1493 cm'1
Stage B: Monohydrochloride of methyl ester of 0-(9,10dimethoxy 1,2,3,4,5,6-hexahydro 4-oxo 8-benz(e)azulenyl) DLhomoserine.
ml of hydrochloric acid in ethyl acetate is added in three lots to 6 g of product prepared in Stage A in 10 ml of ethyl acetate then agitation is carried out for 16 hours at ambient temperature. The solvent is evaporated off under reduced pressure and 0.656 g of expected product is obtained which is used as it is for the following stage.
Stage C: 0-(9,10-dimethoxy 1,2,3,4,5,6-hexahydro 4-oxo 8benz(e)azulenyl) N-[(8-quinolinyl) sulphonyl] DL-homoserine.
0.656 g of the product obtained above is taken up in 5 ml of dichloromethane, 1 ml of triethylamine and 0.638 g of 8-chlorosulphonyl quinoline are added and agitation is carried out for 2 hours at ambient temperature. After evaporation of the solvents under reduced pressure and chromatography on silica (eluant: CHCl2-MeOH 95-5), 0.956 g of expected product is recovered.
Stage D: Methyl ester of 0-[4-[(4,5-dihydro 1H-imidazol-2-yl) hydrazono] 9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8benz(e)azulenyl] N- [ (8-quinolinyl) sulphonyl] DL-homoserine.
0.9 g of the product of the preceding Stage A, 5 ml of butanol and 0.6 g of the following cyclic aminoguanidine hydrobromide: (4,5-dihydro lH-imidazol-2-yl) hydrazine, are agitated for 16 hours at 12O’C, the solvent is evaporated off under reduced pressure and 0.786 g of expected product is obtained, used as it is for the following stage.
Stage E: 0-[4-[(4,5-dihydro 1H-imidazol-2-yl) hydrazono]
AP.00806
9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8-benz(e)azulenyl] N[(8-quinoiinyl) sulphonyl] DL-homoserine.
The solution containing 0.786 g of the product obtained in the preceding stage, 5 ml of methanol and 2 ml of 2N soda is agitated for 2 hours at ambient temperature, then neutralized with 2 ml of 2N hydrochloric acid and agitation is continued for 10 minutes. After evaporation under reduced pressure, the crude product is purified by chromatography on silica, eluting with a CH2C12-methanol-ammonium hydroxide mixture (80-20-4). 0.438 g of expected product is obtained after recrystallization from methanol.
Rf = 0.40 (CHCl2-MeOH-NH4OH 80-20-4).
NMR Spectrum (DMSO) ;j.. if J · >
1.81 (ws) ch2 in position 9
15 2.40 to 3 . .20 the =c-ch2’s
3.35 (w) the =N-CH2's
3.55 (ws) the =C-0Me’s
6.63 (ws) H4
7.58 (dd) H*3
20 7.67 (t) H,6
8.19 (d) , 8.29 (d) H’s and H'7
8.45 (d) h4
8.90 (d) H2
7.31 (ws) }
25 7.97 } mob die H' ' s
10.40 (f) }
12.62 }
EXAMPLE 29: Monohydrochloride of O-[4-[(4,5-dihydro 1Himidazol-2-yl) hydrazono] 9,10-dimethoxy 1,2,3,4,5,630 hexahydro 8-benz(e)azulenyl] N-C[3-[4-(3-pyridinyi) 1Himidazol-l-yl] propoxy] carbonyl] DL-homoserine.
Stage A: Methyl 4-[[9,10-dimethoxy 1,2,3,4,5,6-hexahydro 4oxo 8-benz(e)azulenyl] oxy] 2-isocyanato butanoate.
450 mg of the amine obtained in Stage B of Example 28 is agitated for 10 minutes at 0°C in 10.2 ml of a saturated aqueous solution of sodium bicarbonate and 10.2 ml of dichioromethane. 204 mg of triphosgene in solution in 2 ml of dichioromethane is added to the organic phase of the
V £ I· 0 / 8 6 /d/dV
AP.00806 reaction medium, agitation is carried out for 10 minutes, followed by extraction with dichloromethane, the extracts are dried, the solvent is evaporated off under reduced pressure and 430 mg of expected product is obtained which is used as it is for the following stage.
Stage B: 0-[9,10-dimethoxy 1,2,3,4,5,6-hexahydro 4-oxo 8benz(e)azulenyl] N-[ [3 - [4-(3-pyridinyl) 1H-imidazol-1-yl] propoxy] carbonyl] DL-homoserine.
430 mg of the product obtained in Stage A in 20 ml of 10 di chloromethane is cooled down to 0°C and 414 mg of the alcohol prepared as in Preparation 10 in 10 ml of dichloromethane is added. The reaction medium is allowed to return :5 * to ambient temperature, maintained under agitation for 48 hours, the solvent is evaporated off under reduced pressure, the residue is chromatographed on alumina (eluant: CH2C12MeOH) and 298 mg of expected product is recovered.
Stage C: Monohydrobromide of O-[4[(4,5-dihydro 1H-imidazol-2yl) hydrazono] 9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8benz(e)-azulenyl] N-[[3-[4-(3-pyridinyl) 1H-imidazol-1-yl)
0 propoxy] carbonyl] DL-homoserine.
The operation is carried out as in Example 24 Stage B starting with 277 mg of the product obtained in Stage B above and 164 mg of cyclic aminoguanidine hydrobromide in 13 ml of butanol. After chromatography on alumina (eluant: CH2C123 25 MeOH 95-5), 289 mg of expected product is obtained.
IR Spectrum (CHC13)
C=O 1746 (sh) 1723 (max) οη'^ conjugated sys.} + aromatic } 1668, 1625(F), 1599(sh), 1551, 1509, 1489 cm1 30 + amide II }
OH 3618 cm1
Stage D: Monohydrochloride of 0-[4-[(4,5-dihydro lH-imidazol2-yl) hydrazono] 9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8benz(e)azulenyl] N-[[3-[4-(3-pyridinyl) 1H-imidazol-1-yl]
5 propoxy] carbonyl] DL-homoserine.
0.3 ml of N soda is added to 277 mg of product obtained in Stage C above in 10 ml of ethanol, agitation is carried out for 30 minutes, 10 ml of water is added, the reaction
AP/P/ 98/01342
AP.0 0 8 0 6 medium is acidified to a pH of 2.5 using N hydrochloric acid, the solvents are evaporated off under reduced pressure, the residue is chromatographed on silica (eluant: CH2Cl2-MeOHNH40H 40-10-2), the filtrate is evaporated under reduced pressure, the residue is taken up in isopropyl ether, the precipitate is filtered off, dried and 126 mg of expected product is collected.
10 NMR 1.78 1.90 Spectrum (DMSO) (m) (2H) } to 2.30 (m) (5H) } the 3 -CH2's
1.60 to 2.90 (m) (8H) the CH2-C=1s
3.53 (ws) («4Η) n-ch2-ch2-n
3.69 (s), 3.71 (s) ch3o-c=
3.90 to 4.20 (m) (7 to 8H) the CH2's and CH
15 6.73 (s) h4
7.20 (d, wide) co-nh-ch-
7.35 (dd) H’S
8.04 (d) Η-4
8.37 (wd) H'e
20 8.94 (ws) h'2
7.72 (s), 7.80 (s) CH=imidazole.
EXAMPLE 30; 5-[[4-[(4,5-dihydro 4-oxo IH-imidazol-2-yl) hydrazono] 9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8-benz(e)azulenyl] oxy] pentanoic acid.
300 mg of the product prepared in Stage A of Example 3 in 6 ml of ethanol is mixed at ambient temperature with 61 mg of sodium bicarbonate and 0.7 ml of ethyl bromoacetate. The solvents are evaporated off, the residue is chromatographed on silica (eluant: CH2Cl2-MeOH 95-5) and 139 mg of intermediate ethyl ester is obtained. 110 mg of this ester is mixed for 2 hours at ambient temperature with 1 ml of ethanol in the presence of 0.5 ml of 2N soda. After neutralization of the reaction medium using 2N hydrochloric acid, the precipitate formed is filtered off, dried and 44 mg of expected product is recovered.
NMR Spectrum (DMSO) «1.73 (m) (6H)
AP/P/ 9 8/01342 central CH2's and CH2 in position
AP . ο ο 8 Ο 6
66
2.30 (t) (2H) =c-ch2
2.30 to 3.20 =c-ch2
3.73 (s), 3.75 (s) Φ-OMe
3.83 (ws) =C-N-CH.
4.02 (t) Φ-0-Οί2
6.76 (s) h4
7.20 (ws) (IH) }
8.28 (ws) (IH) } mobile j
12.04 (IH) }
EXAMPLE 31: 0- [9,10-dimethoxy 1,2,:
[(4,5,6,7-tetrahydro 1Η-1,3-diazepin-2-yl) hydrazono] 8benz(e)azulenyl] N-[(phenylmethoxy) carbonyl] DL-homoserine.
g of the compound prepared in Example 24 Stage A in
5 ml of butanol and 0.9 g of cyclic aminoguanidine prepared as in Preparation 11 are mixed together for 16 hours at 130°C. The solvent is evaporated off under reduced pressure, the residue is chromatographed on silica (eluant: CH2Cl2-MeOH 9010) and 0.8 g of intermediate ester is obtained which is agitated at ambient temperature for one hour 30 minutes in 3 ml of methanol with 2 ml of 2N soda. After neutralizing the reaction medium using 2N hydrochloric acid and evaporation of the solvents under reduced pressure, the residue is chromato-graphed on silica (eluant: CH2Cl2-MeOH25 NH4OH 90-15-2) and
AP/P/ 9 8/01342
0.22 g of expected product is recovered.
EXAMPLE 32: 0-(9,10-dimethoxy 1,2,3,4,5,6-hexahydro 4[(3a,4,5,6,7,7a-hexahydro lH-benzimidazol-2-yl) hydrazono] 8benz(e)azulenyl] N-[(phenylmethoxy) carbonyl] DL-homoserine.
The operation is carried out as in Stages B and C of
Example 24 starting with 200 mg of the compound prepared in Example 24 Stage A and 176 mg of cyclic amino guanidine prepared as in Preparation 12. 102 mg of intermediate ester is recovered, 100 mg of which is used for the saponification reaction. 59 mg of expected is obtained.
Rf = 0.24 (CH2Cl2-MeOH-NH4OH 85-15-3).
AP.00806
Pharmaceutical compositions
Tablets were prepared corresponding to the following formula:
- Product of Example 1 50 mg
- Excipient (talc, starch, magnesium stearate)
SQ for a tablet made up to 120 mg
Pharmacological study of the products of the invention
- Study of the products of the invention on the displacement of the binding: Vitronectin/Vitronectin receptor (a^^)
Protocol:
MaxiSorp 96-well plates are coated overnight at 4°C, with 100 μΐ of human Vitronectin (cf Yatohgo et al. Cell., λ: -..1
Structure and fraction 13: 281-292 (1988)) at 2 ^g/ml, (Dilution in coating buffer).
The next day, the wells are emptied and the ligands (Vitronectin) are then fixed (see fixing buffer) for one hour at ambient temperature under gentle agitation.
The wells are washed six times (see washing buffer), then the following are added to each well and in this order:
- 40 μΐ of incubation buffer,
- 10 μΐ of the dilution of the product to be tested, (the products are diluted in a 50/50 mixture of DMSO-H2O)
- 50 μΐ of human 0^3 receptor (cf Pytela et al. Methods Enzymol (1987) 144:475) (dilution in incubation buffer, to be adapted according to the receptor batch and according to the ligand).
The ligand, the human 0^3 receptor and the products to be studied are incubated for 3 hours at ambient temperature under gentle agitation.
The wells are again washed six times, then incubated for hours at ambient temperature under gentle agitation, in the presence of 100 μΐ of anti-receptor, 4B12-HRP antibody coupled to a peroxidase (the 4B12-HRP antibody is diluted in an incubation buffer. The dilution is to be adapted according to the receptor batch).
The wells are then washed six times before the ligand-receptor binding is measured by means of a peroxidase revealer kit (TMB Microwell Peroxidase Substrate System
AP/P/9 8 /01 3 42
AP. Ο Ο 8 Ο 6
W Ί-Ιή68
Kirkegaard: Ref. cat. 50-76-00).
This kit contains a bottle A of substrate (3,3',5,5'tetramethylbenzidine at 0.4 g/1) and a bottle Β (H2O2 at 0.02% in a citrate/citric acid buffer). Extemporaneously, a volume of A is mixed with a volume of B, then the reaction mixture is distributed at a rate of 100 μΙ/well. The enzymatic reaction develops over 12 hours for Vitronectin/ct^g, then its development is stopped by the addition of 100 μΐ of 1M phosphoric acid.
The optical density is measured at 450 nm.
Buffers:
- coating buffer: Carbonate 0.05 M, NaOH pH 9.6
- fixing buffer: PBS containing 0.5% BSA (pH 7.4)
- washing buffer: PBS containing 0.05% Tween 20 (pH 7.4)
- incubation buffer:
. 50 mM TRIS pH 7.4 . 0.5% BSA . 0.05% Tween 20 . 1 mM MnCl2 . 50 μΜ CaCl2 . 50 μΜ MgCl2 . 100 mM NaCl.
Expression of the results:
The following curve is traced: the percentage of binding of the human vitronectin as a function of the logarithm of the concentration of each product tested.
For each product the IC50 is determined according to the following formula:
IC50 = (BO + Bmin)/2
BO = Maximum binding in the absence of any product Bmin = Minimum binding in the presence of the highest concentration of product.
- Test of mouse calvarium Principle
Injection of a tracer dose of 45Ca (CaCl2) to gestating female mice in order to study bone resorption by measuring the release of 45Ca from the skullcaps of new-born mice. Purpose £ I. 0 / 8 6 Zd/dV
AP . 0 0 8 0 6
Mi.*’'
Determination of the activity of a molecule on bone resorption, ex-vivo study.
Products
1) Product to be tested:
Vehicle: DMSO, H2O/BSA (0.1%)
Dose: Variable (10 μΜ in screening).
2) Reference products:
Echistatin (ref. H-9010-BACHEM)
Vehicle: H2O/BSA
Dose: 10 μΜ.
3) Radioactive tracer:
45Ca in the form of an aqueous solution of CaCl2 - ref. CES3 AMERSHAM or NEZ-013 NEN.
Vehicle: Physiological serum
Dose: 25 pCi/mouse/0.4 ml Culture medium
CMRL 1066 with phenol red (ref. 041-01535 M/GIBCO) supplemented by 0.1% BSA and penicillin/streptomycin.
Method
1) Injection of 45Ca to gestating mice (OF1, strain: Swiss) a) Preparation of the labelled solution:
190 μΐ of the mother solution of calcium at 2 mci/ml is added to 6 ml of physiological serum.
b) Injection:
On the 17th day of gestation the mice receive 400 μΐ of this solution by intravenous route, that is 25 μΟϊ/πκχιββ.
2) Removal of the tissue (skullcap (calvarium))
Six days after their birth the new-born mice are 30 decapitated, then the head is recovered, and the skin is incised from the nape to the front. The skullcap is removed by cutting it out with scissors, and using a punch two exactly identical half-calvaria (one on the left and one on the right) are cut from the parietal bones. One will serve as the control, the other will be used to test the product to be studied.
3) Rinsing phase
Each half calvarium is placed in a well of a 24-well
AP/P/ 9 8 / 0 1 3 4 2
AP. ο Ο 8 Ο 6 plate, containing 1 ml of medium, on a 100 μτη. polyethylene and nylex support, in order to avoid all contact with the bottom of the well.
After 24 hours, the polyethylene supports carrying the 5 calvaria are transferred into new 24-well plates containing ml of fresh medium and the products to be tested or their solvents. 200 μΐ of medium from the first plates is removed from each well and a first count of the radioactivity is carried out (value A).
This change of medium allows all the mechanical stress associated with the removal to be eliminated.
4) Resorption phase hours after putting the tissues in contact with the studied products, 200 μΐ of medium is removed from each well and counted (value Β), so as to determine the quantity of 4^Ca released from the medium during the so-called resorption phase.
The calvarium is then completely demineralized in 1 ml of 5% trichloracetic acid and after digestion, 200 μΐ is also removed and counted so as to determine the quantity of calcium remaining in the bone (value C).
Expression of the results
A % of bone resorption is calculated for each halfcalvarium (each well) in the following manner:
% bone resorption = dpm B/dpm (A+B+C) x 100
The sum of dpm A+B+C represents the quantity of 45Ca incorporated in each bone part on the day of removal.
In order to measure the effect of a product, the ratio of the percentage of bone resorption of the treated well and of the corresponding control well is calculated for each point. The value found called the resorption index is comprised between 0 and 1 if the product inhibits bone resorption and is >1 if the product potentializes it. The average of the 6 indices (since there are 6 points/group) of each product is then calculated which gives one index/ product. If this index is subtracted from the value 1, the inhibitory power of the product is obtained, which can be
AP/P/ 9 8 / 0 1 3 4 2
AP .00806 expressed as a percentage.
Furthermore a statistical test (Student T-test) is carried out by comparing point/point the individual resorption indices.
AP/P/ 9 8 / 0 1 3 4 2
AP . Ο Ο 8 Ο 6
RESULTS :
Examples Competition test Vn/VR ( ) binding ICc;n en μΜ Mouse cavarium %· inhibition at ΙΟμΜ
EX. 2 0,45 19
EX. 3 2,1 -
EX. 6 0,11 7,5
EX. 8 2,79 - .
EX. 10 0,8 8
EX. 11 0,05 7
EX. 22 2,36 -
EX. 12 0,35 12
EX. 14 0,75 14
EX. 24 0,03 18
EX. 20 0,079 11
EX. 21 0,037 -
EX. 25 0,013 26
EX. 26 0,006 30
EX. 27 0,170 39
EX. 28 0,015 27
EX. 29 0,028 18
EX. 31 0,055 20
EX. 32 0,035 -
ΑΡ;?/ 9 8 / 0 1 3 4 2
AP.00806

Claims (21)

1) Compounds of general formula (I):
R
N —G (I) in which R-^ represents a -C=C-[A]-[B]-CORg,
15 -CH=CH- [A] - [B]-CORg, - (¾) 2 - [A] - [B] - CORg, -O-[A] - [B]-CORg, -CH2CO-[A]-[B]-CORg group, -[A]- representing
- either a bivalent hydrocarbonated radical derived from a saturated or unsaturated, linear or branched structure containing 1 to 12 carbon atoms and 1 to 6 heteroatoms chosen
20 from oxygen, nitrogen or sulphur atoms,
- or a bivalent radical derived from a saturated or unsaturated, linear or branched acyclic hydrocarbon containing 1 to 12 carbon atoms, [B] representing a phenyl radical, a CH[Z] radical, or a
25 single bond,
Z represents a hydrogen atom, one of the following groups:
(D)0_g-NRaRb, (D)O.g-NH-S02-Rc, (D)θ_g-NH-CO2-Rc, (D)0_g-NH-CO-Rc, (D)θ_g-NH-SO2-NH-Rc, (D)θ_g-NH-CO-NH-Rc, (D)o_g-C02-Rc, (D)0_g-SO2-Rc, (D)0_g-CO-Rc or (D)0_g-Rc in
30 which (D)0_g is a bivalent radical derived from a saturated or unsaturated, linear or branched acyclic hydrocarbon containing 0 to 6 carbon atoms,
Ra, Rb and Rc represent a hydrogen atom, a (CH2)0_3-Ar radical in which Ar represents a carbocyclic aryl
35 group containing 6 to 18 carbon atoms, a (CH2)0_3-Het radical in which Het represents a radical derived from a saturated or unsaturated, aromatic or non-aromatic heterocycle containing
1 to 9 carbon atoms and 1 to 5 heteroatoms chosen from
AP/P/ 9 8 / 0 1 3 42
AP. Ο Ο 8 Ο 6 oxygen, nitrogen or sulphur atoms, a (CH2)0_3-Alk radical in which Aik represents a radical derived from a saturated or unsaturated, linear, branched or cyclic, non-aromatic hydrocarbon, containing 1 to 12 carbon atoms, the Het, Ar and
5 Aik radicals being able to be non-substituted or substituted, or also, Ra and Rb represent together with the nitrogen atom to which they are linked a saturated or unsaturated, aromatic or non-aromatic, nitrogenous heterocycle optionally containing one or more heteroatoms chosen from oxygen,
10 nitrogen or sulphur atoms, this radical being able to be substituted or non-substituted,
- Rg represents a hydroxyl radical, an O-Alk, O-Ar, NH2, NH-Alk, N(Aik)2 radical or the remainder of a L or D amino acid, Aik and Ar being as defined previously and being
15 optionally substituted or not substituted,
- R2 and R3, identical or different, represent either a hydrogen atom, a hydroxyl radical, an O-Alk radical or an 0-(CH2)Q_3-Ar radical, Aik and Ar being as defined previously, or R2 and R3 form together with a ring of
20 -0-(CRdRe)n- type, n being an integer from 1 to 5, Rd and Re independently of each other represent a hydrogen atom, an alkyl radical containing 1 to 6 carbon atoms, or a phenyl radical,
- R4 represents a hydrogen atom, a halogen atom, one of the
25 following groups: hydroxyl, amino, nitro, cyano, CF3, acyl or acyloxy containing 1 to 12 carbon atoms, alkyl, alkenyl, alkynyl, aikylthio, alkoxy, alkylamino, dialkyiamino, dialkylaminoalkyl, dialkylaminoalkyloxy, in which the term alkyl contains 1 to 6 carbon atoms,
30 - R5 represents a hydrogen atom, a hydroxyl radical, a halogen atom, an O-Alk radical or an 0-(CH2)0_3-Ar radical, Aik and Ar being as defined previously,
- G represents, either a radical of formula Gl
-N—(Het')
Rh
AP. Ο Ο 8 Ο 6 in which Rh is a hydrogen atom or an Aik group as defined previously and (Het1) is a heterocyde of general formula:
// λ -C (H) in which (H) forms, with the N=C-NH- unit, the remainder of a saturated or unsaturated, mono- or bicyclic, aromatic or non10 aromatic heterocycle containing 1 to 9 carbon atoms and 2 to 5 heteroatoms chosen from oxygen, nitrogen and sulphur atoms, this radical being able to be substituted or non-substituted,
- or an NRaRb radical (radical G2), Ra and Rb being as defined above,
15 - or a (Het) radical (radical G3) as defined above,
- or an -NRh-C(=X)-NHRc radical (radical G4), in which X is a sulphur or oxygen atom or NH, Rh and Rc are as defined previously,
- or an -NRh-SO2Rc radical, (radical G5), in which Rh and Rc
20 are as defined previously, the dotted lines represent an optional second bond, as well as the addition salts with acids and bases and the esters.
2) Compounds of general formula (I) as defined in claim 1, corresponding to general formula (I'):
:N·
AP/P/ 98/01342 (I') in which R'-j_ represents one of the following groups:
35 -C-C-[A']-[B']-COR’g, -CH=CH-[A']-[B']-COR*g,
- (CH2)2- [A’]- [B‘]-COR’g, -0- [A'] - [B*]-COR’g,
-CH2CO-[A’]-[B]-COR’g, -[A1]- representing a bivalent alkylene, alkenylene or alkynylene radical containing 1 to
AP . Ο Ο 8 Ο 6 carbon atoms, [B1] representing a CH(Z') radical or a single bond,
Z’ represents a hydrogen atom, one of the following groups: (CH2)0_g-NRaRb, (CH2)0_6-NH-SO2-Rc, (CH2)q.g-NH-CO2-Rc, 5 (¾) 0.g-NH-CO-Rc, (CH2) O.g-NH-S02-NH-Rc, (CH2)0_g-NH-CO-NH-Rc, (ch2) 0-6'CO2'Rc' (°¾) 0-6S02'Rc' (CH2)0_g-CO-Rc or (CH2)0_g-Rc, Ra, Rb and Rc being as defined in claim 1, R'g represents an OH, amino or alkoxy radical containing 1 to 8 carbon atoms, optionally substituted by one
10 or more radicals chosen from hydroxy, amino, phenyl, alkylamino or dialkylamino radicals,
R’2 and R'3 represent a hydrogen atom or a methoxy radical, and G is as defined in claim 1, the dotted lines represent an optional second bond, as well as the addition salts with
15 acids and bases and esters.
3) Compounds of general formula (I) as defined in claim 1 or 2 in which Rg represents one of the following groups: -OH, -och3, -och2ch3, -o-(ch2)2-oh, -o-ch2-ch-ch2oh,
I
20 OH
-0-(CH2)2-NH2, -0-(CH2)2-N-(CH3)2, -NH2 or -0-(CH2)-phenyl, as well as the addition salts with acids and bases and esters .
4) Compounds of general formula (I) as defined in claim 1, 2
25 or 3 in which R-]_ represents an 0-(CH2)0_g-CH(Z')-COOH or
-(CH2)q_7-CH(Z’)-COOH group, as well as the addition salts with acids and bases and the esters.
5) Compounds of general formula (I) as defined in any one of claims 1 to 4, in which (Z') is a hydrogen atom, as well as
30 the addition salts with acids and bases and the esters.
6) Compounds of general formula (I) as defined in any one of claims 1 to 4, in which (Z*) is the (CH2)Q_g-NH-CO2-Rc or (CH2)Q_g-NH-Rb group, Rb and Rc being as defined in claim 1, as well as the addition salts with acids and bases and the
35 esters.
7) Compounds of general formula (I) as defined in claim 6, in which Rb and Rc are (CH2)0_3-Ar or (CH2)Q_3-Alk groups, Ar and Aik being as defined in claim 1 and being able to be
AP/P/ 98/01 342
AP.00806 substituted or non-substituted, as well as the addition salts with acids and bases and the esters.
8) Compounds of general formula (I) as defined in one of claims 1 to 7, in which G is a G4 group of general formula
5 -NH-C(=NH)-NHRc, Rc being as defined in claim 1, as well as the addition salts with acids and bases and the esters.
9) Compounds of general formula (I) as defined in claim 8, in which Rc is a hydrogen atom, as well as the addition salts with acids and bases and the esters.
10
10) Compounds of general formula (I) as defined in one of claims 1 to 7, in which G is an NH-(Het') group, (Het') being as defined in claim 1.
11) Compounds of general formula (I) as defined in claim 10 in which G represents the following heterocycles:
AP/P/ 98/01342 p being an integer equal to 2, 3 or 4, these heterocydes being substituted or non-substituted, as well as the addition salts with acids and bases.
35
12) Compounds of general formula (I) as defined in claim 10 or 12, in which G is the group
AP . Ο Ο 8 Ο 6 ρ being an integer equal to 2, 3 or 4, as well as the addition salts with acids and bases and the esters.
13) Compounds of formula (I) as defined in claim 1 the names of which follow:
10 - 4-((4-((aminoiminomethyl)hydrazono)-9,10-dimethoxy-l,
2.3.4.5.6- hexahydro-8-benz(e)azulen-yl)oxy)-butanoic acid
.. - 5-( (4-( (aminoiminomethyl) hydrazono)-9,10-dimethoxy-l,
2.3.4.5.6- hexahydro-8-benz(e)azulen-yl)oxy)-pentanoic acid,
- 5-((4-((aminoiminomethyl) hydrazono)-8,10-dimethoxy-l,
15 2,3,4,5,6-hexahydro-9-benz(e)azulen-yl)oxy)-pentanoic acid,
- 6-((4-((aminoiminomethyl)hydrazono)-9,10-dimethoxy-l,
2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-hexanoic acid,
- 7-((4-((aminoiminomethyl) hydrazono)- 9,10-dimethoxy-1,
2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-heptanoic acid,
20 - 5- ((9,10-dimethoxy-1,2,3,4,5,6-hexahydro-4-((4,5-dihydro1H-imidazol-2-yl)hydrazono) -8-benz(e)azulenyl)oxy)-pentanoic acid,
- ethyl 5-((4-((aminoiminomethyl)hydrazono)-9,10-dimethoxy-l,
2,3,4,5,6 -hexahydro- 8 -benz(e)azulenyl)oxy)-pentanoate X s? 25 hydrochloride,
- 4-((4-((aminoiminomethyl)hydrazono)-8,9-dimethoxy-l,
2.3.4.5.6- hexahydro-10-benz(e)azulenyl)oxy)-butanoic acid,
- 5-((4-((aminoiminomethyl)hydrazono)-8,9-dimethoxy-l,
2.3.4.5.6- hexahydro-10-benz(e)azulenyl)oxy)-pentanoic acid,
30 - 5-((4-(((amino)carbonyl)hydrazono)-9,10-dimethoxy-l,
2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-pentanoic acid,
- 5-((4-(((amino)thiocarbonyl)hydrazono)-9,10-dimethoxy1.2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-pentanoic acid,
- 4-((4-((aminoiminomethyl)hydrazono)- 8,10-dimethoxy35 1,2,3,4,5,6-hexahydro-9-benz(e)azulenyl)oxy)-butanoic acid,
- 6-((4-((4,5-dihydro-lH-imidazol-2-yl)hydrazono)-9,10dimethoxy-l, 2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)-hexanoic acid,
AP/P/ 9 8 / 0 1 3 42
AP. Ο Ο 8 Ο 6
- 5-((4-((aminoiminomethyl)hydrazono)-9,10-dimethoxy1.2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-3,3-dimethyl-4oxo-pentanoic acid,
- 5-((4-((4,5-dihydro-1H-imidazol-2-yl)hydrazono)-9,105 dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)-3,3dimethyl-4-oxo-pentanoic acid,
- 5-((4-((aminoiminomethyl)hydrazono)-9,10-dimethoxy1.2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-pentanoic acid hydrochloride,
10 - 4-((4-((4,5-dihydro-1H-imidazol-2-yl)hydrazono)-9,10dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)butanoic acid, j
- 5-((8-((-aminoiminomethyl)hydrazono)- 6,7,8,9,10,11hexahydro-azuleno(5,6-d)-1,3-benzodioxol-4-yl)oxy)-pentanoic
15 acid,
- 5-((8-((aminoiminomethyl)hydrazono)-2,2-diphenyl6,7,8,9,10,11-hexahydro-azuleno(4,5-e)-(1,3)-benzodioxol-4yl)oxy)-pentanoic acid,
- 4-((9,10-dimethoxy-4-((1,4,5,6-tetrahydro-2-pyrimidinyl)
20 hydrazono)-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)butanoic acid,
- 2-((4-((4,5-dihydro-1H-imidazol-2-yl)hydrazono)-9,10dimethoxy-1,2,3,4,5,6-hexahydro- 8 -benz(e)azulenyl)oxy)ethanoic acid,
25 - 3-( (4-( (4,5 - dihydro-1H-imidazol-2-yl) hydrazono)-9,10dimethoxy-1,2,3,4,5,6-hexahydro-8-benz(e)azulenyl)oxy)propanoic acid,
- 4-((4-((4,5-dihydro-lH-imidazol-2-yl)hydrazono)1.2.3.4.5.6- hexahydro-89-benz(e)azulenyl)oxy)-butanoic acid,
30 - 4-((4-((4,5-dihydro-lH-imidazol-2-yl)hydrazono)1.2.3.4.5.6- hexahydro-8-benz(e)azulenyl)oxy)-butanoic acid,
- 0-[4[(4,5-dihydro-1H-imidazol-2-yl)hydrazono]-9,10dimethoxy-1,2,3,4,5,6-hexahydro-8-benz[e]azulenyl]-N((phenylmethoxy)carbonyl]-DL-homoserine,
35 - 0-[4[(4,5-dihydro-1H-imidazol-2-yl)hydrazono]-1,2,3,4,5,6hexahydro-8-benz[e]azulenyl]-N-[(phenylmethoxy)carbonyl]-DLhomoserine,
- 0-[4-[(1,2,3,4-tetrahydro 6-pyrimidinyl) hydrazono] 9,10AP/P/ 9 8 / 0 1 3 4 2
ΑΡ. Ο Ο 8 Ο 6 dimethoxy 1,2,3,4,5,6-hexahydro 8-benz[e]azulenyl] N[(phenylmethoxy) carbonyl] DL-homoserine,
- (2,3-dihydroxypropyl) ester of 0-(9,10-dimethoxy
1,2,3,4,5,6-hexahydro 4-[(1,4,5,6-tetrahydro 2-pyrimidinyl)
5 hydrazono]]-8-benz(e)azulenyl] N-[(phenylmethoxy) carbonyl] DL-homoserine,
- 0-[4-[ (4,5-dihydro IH-imidazol-2-yl) hydrazono] 9,10dimethoxy 1,2,3,4,5,6-hexahydro 8-benz(e)azulenyl] N-[(8guinolinyl) sulphonyl] DL-homoserine,
10 - monohydrochloride of 0-[4-[(4,5-dihydro IH-imidazol-2-yl) hydrazono] 9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8-benz(e)azulenyl] N-[[3 -[4-(3-pyridinyl) lH-imidazol-l-yl] propoxy] carbonyl] DL-homoserine,
- 5-[[4-[(4,5-dihydro 4-oxo IH-imidazol-2-yl) hydrazono]
15 9,10-dimethoxy 1,2,3,4,5,6-hexahydro 8-benz(e)azulenyl] oxy] pentanoic acid,
- 0-[9,10-dimethoxy 1,2,3,4,5,6-hexahydro 4-[ (4,5,6,7,tetrahydro lH-l,3-diazepin-2-yl) hydrazono] 8-benz(e)azulenyl] N-[(phenylmethoxy) carbonyl] DL-homoserine,
20 - O-[9,10-dimethoxy 1,2,3,4,5,6-hexahydro 4-[(3a,4,5,6,7,7ahexahydro lH-benzimidazol-2-yl) hydrazono] 8-benz(e)azulenyl] N-[(phenylmethoxy) carbonyl] DL-homoserine.
14) Preparation process for the compounds of formula (I) as defined in claim 1, characterized in that a compound of
25 formula (II):
AP/P/ 9 8/01342
35 in which R2 , R3, R4 and Rg are as defined in claim 1 with the exception of the hydroxyl value, is subjected either to the action of a compound of formula (FI) in the presence of a base,
AP. 0 0 8 0 6
..7
Hal-[A]-[B]-CORg (Fl) or a compound of formula (F^) in the presence of a phosphine 5 and of diethyl azodicarhoxylate:
HO-[A]-[B]-CORg (F’-l) in which Hal is a halogen atom, [A], [B] and Rg are as
10 described previously, [B] also being able to represent the
-CH- group, P being a protective group of the amine I
NH-P function, in order to obtain a compound of formula (Ilia): 15 (Ilia)
AP/P/ 98/01342 or to the action of an activating group then of a compound of formula (F2) in the presence of a catalyst:
H-C=C-[A]-[B]-C-Rg (F2) in order to obtain a compound of formula (lllb):
AP. Ο Ο δ Ο 6 (Illb) which compounds of formula (Ilia) or (Illb) are subjected to the action of a compound of formula (F3):
h2n-g (F3) in which G is as defined in claim 1, in order to obtain the compounds of formula (IVa) and (IVb) corresponding to certain products of formula (I) :
:--¾
Zi :N —G (IVa)
AP/P/ 9 8/01342
O
II
Rg—C35
[]—[*]
N—G (IVb)
AP . Ο Ο 8 Ο 6 :/¾ which are subjected, if appropriate, in a suitable order, to one or more of the following reactions:
- the action of a base or an acid in order to cleave the ester and to obtain the corresponding acid,
5 - the action of a reducing agent suitable for partially or totally reducing the unsaturations,
- the action of a hydration agent of the triple bond,
- the action of a dealkylation agent,
- to the action of a deprotection agent of the NH-P function
10 in beta position of CO-Rg when [B] represents the CH-NHP group,
- to the formation of the NH-SO2Rc, NH-C02Rc, NHCORc, NH-SO2-NH-Rc, NH-CO-NHRc group from the corresponding amine in beta position of CORg, in order to obtain the
15 corresponding compounds of formula (I) which are subjected if appropriate to the action of an acid or a base in order to obtain the corresponding salts or to the action of an esterification agent in order to obtain the corresponding esters.
20
15) Preparation process of the compounds of formula (I) as defined in claim 1, characterized in that beforehand a compound of formula (II) is subjected to the action of a compound of formula (F3) in order to obtain a compound of formula (IIIc):
(IIIc)
AP/P/ 9 8 / 0 1 3 42
35 which compound of formula (IIIc) is subjected if appropriate after protection of G to the action of a compound of formula (FI) , (F’-J or (F2) then if appropriate to a deprotection reaction of G, in order to obtain the corresponding compounds
AP. Ο Ο 8 Ο 6 of formula (IVa) and (IVb) which are then subjected, if appropriate, to the different reactions as defined in claim 14, the compounds of formulae (II), (FI), (F *-^) , (F2), (F3), (IVa) and (IVb) being as defined in claim 14.
5
16) Preparation process of the products of formula (II) as defined in claim 14 in which R2, R3, R4 and R5 are hydrogen atoms and OH is in position 8, 9 or 10, characterized in that (i) a compound of formula (a):
in which 0-(Aik) is in meta or para position of the alkylcarboxylic group, (Aik) being as defined in claim 1, is subjected to the action of a halogenation agent in order to
20 obtain the corresponding acyl halide, (ii) which is subjected to the action of a reagent of formula (b) :
Z fr £ I 0 / 8 6 /d/dv in which R{I) and R(II), identical or different, represent an alkyl group containing 1 to 6 carbon atoms, or R(I) and R(II)
30 together with the nitrogen atom to which they are linked, represent a saturated or unsaturated heterocycle with 5 or 6 members optionally containing another heteroatom chosen from and N, in order to obtain a compound of formula (c):
AP.ο ο δ Ο 6 (Alk)O (c) (iii) which is subjected to the action agent in order to obtain a compound of of a halogenation formula (d):
%*/· in which Hal-|_ represents a halogen atom, (iy) which is subjected to the action of a Lewis acid, in order to obtain a compound of formula (e):
AP/P/ 9 8 / 0 1 3 4 2 (v) which is subjected to a dealkylation reagent in order to obtain the product of formula (IIF) corresponding to the expected monosubstituted product of formula (II):
17) Preparation process of the compounds of general formula
AP . Ο ΰ 8 Ο 6 (II) as defined in claim 14 and in which R2 is either an OAlk group, or an 0-(CH2)0_3-Ar group and R3, R4 and R5 are hydrogen atoms, OH and R2 being in position 8, 9 or 10, characterized in that the compound of formula (a'):
in which R2 and O-Alk are in meta or para position of the alkyl carboxylic group, is successively subjected to reactions (i), (ii), (iii), (iv) and (v) in order to obtain the product of formula (IIG) corresponding to the expected
20 bisubstituted product of formula (II):
AP/P/ 98/01342
18) Preparation process of the compounds of general formula 30 (II) as defined in claim 14 and in which R2 and R3 represent an 0-(Aik) or 0-(CH2)0_3-(Ar) group, R4 and R5 are hydrogen atoms, OH being in position 9, characterized in that the compound of formula (IIA):
AP . (1 0 8 0 6 (IIA) is subjected to the action of an alkylation reagent, in order to obtain the compound of formula (IIB):
(IIB) which compound of formula (IIB) is subjected:
either to the action of a protection reagent of the diols in a basic medium, in order to selectively obtain the product of
20 formula (IIC):
(IIC) in which P represents the remainder of a protection reagent of the diols,
30 which is successively subjected to the action of a protection reagent of the phenol, a deprotection reagent of the diols, an alkylation agent then a deprotection agent of the phenol in order to obtain the compound of formula (IID) corresponding to the trisubstituted product of formula (II)
35 with OH in position 8:
AP/P/ 9 8/ 01342
AP , Ο Ο 8 Ο 6 (IID) or to the successive action of a protection agent of the phenol, an alkylation agent then a deprotection agent in 10 order to obtain the compound of formula (IIE) corresponding to the trisubstituted product of formula (II) with OH in position 9:
(HE)
19) - As medicaments, the compounds of formula (I) as defined in any one of claims 1 to 12, as well as their pharma-ceutically aceptable addition salts and their esters.
20) As medicaments, the compounds of formula (I) as defined 25 in claim 13.
21) The pharmaceutical compositions containing as active ingredient at least one of the medicaments defined in claim 19 or 20.
APAP/P/1998/001342A 1996-03-20 1997-03-20 Tricyclic compounds having activity specific for integrins, particularly avB3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same. AP806A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9603437A FR2746394B1 (en) 1996-03-20 1996-03-20 NOVEL TRICYCLIC COMPOUNDS, THEIR PREPARATION PROCESS, AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PCT/FR1997/000487 WO1997034865A1 (en) 1996-03-20 1997-03-20 TRICYCLIC COMPOUNDS HAVING ACTIVITY SPECIFIC FOR INTEGRINS, PARTICULARLY αvβ3 INTEGRINS, METHOD FOR PREPARING SAME, INTERMEDIATES THEREFOR, USE OF SAID COMPOUNDS AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Publications (2)

Publication Number Publication Date
AP9801342A0 AP9801342A0 (en) 1998-09-30
AP806A true AP806A (en) 2000-01-28

Family

ID=26232597

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001342A AP806A (en) 1996-03-20 1997-03-20 Tricyclic compounds having activity specific for integrins, particularly avB3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same.

Country Status (21)

Country Link
US (1) US6221907B1 (en)
EP (1) EP0888292B1 (en)
JP (1) JP4091983B2 (en)
KR (1) KR20000064710A (en)
AP (1) AP806A (en)
AT (1) ATE207889T1 (en)
AU (1) AU728852B2 (en)
BG (1) BG63569B1 (en)
BR (1) BR9708231A (en)
CA (1) CA2249471A1 (en)
DE (1) DE69707843T2 (en)
DK (1) DK0888292T3 (en)
EA (1) EA002271B1 (en)
EE (1) EE9800317A (en)
GE (1) GEP20012516B (en)
LV (1) LV12207B (en)
NO (1) NO312459B1 (en)
NZ (1) NZ331778A (en)
SI (1) SI9720021A (en)
SK (1) SK282894B6 (en)
WO (1) WO1997034865A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2768734B1 (en) * 1997-09-24 2000-01-28 Roussel Uclaf NOVEL TRICYCLIC COMPOUNDS, THEIR PREPARATION PROCESS AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2768736B1 (en) * 1997-09-24 2000-05-26 Roussel Uclaf NOVEL TRICYCLIC COMPOUNDS, THEIR PREPARATION PROCESS AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TW538046B (en) 1998-01-08 2003-06-21 Hoechst Marion Roussel Inc Aromatic amides having antiobiotic activities and the preparation processes, intermediates and pharmaceutical composition thereof
FR2786181B1 (en) 1998-11-24 2001-10-26 Hoechst Marion Roussel Inc NOVEL IMINOGUANIDINE DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE19916837A1 (en) * 1999-04-14 2000-10-19 Merck Patent Gmbh New di- or tetrahydro-benzoazulene derivatives, are integrin inhibitors useful e.g. for treating thrombosis, coronary heart disease, arteriosclerosis, tumors, osteoporosis or rheumatoid arthritis
EP1236713A4 (en) 1999-11-18 2004-10-13 Ajinomoto Kk Novel intermediate for sweetener with high sweetness and process for producing the same
KR100523119B1 (en) * 2000-03-16 2005-10-20 에프. 호프만-라 로슈 아게 Carboxylic acid derivatives as ip antagonists
RU2316337C2 (en) 2001-04-24 2008-02-10 Мерк Патент Гмбх Combined therapy by using antiangiogenic agents and tnf-alpha
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
CA2676185C (en) * 2006-12-26 2013-03-12 Centro De Inmunologia Molecular Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
BRPI0806596A2 (en) 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung drug and specific therapy using integrin ligands for cancer treatment
UA104587C2 (en) 2008-03-14 2014-02-25 Биокон Лимитед Monoclonal antibody and a method of use thereof
MX2011012491A (en) 2009-05-25 2011-12-14 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments.
CN102603743B (en) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 Anti-tumor benzazepine[f]azulene derivative, preparation method thereof, and purpose thereof
CA2920368C (en) 2013-07-23 2023-03-21 Centro De Inmunologia Molecular Use of a cd6 binding partner and method based thereon
BR112016027778A2 (en) 2014-05-30 2017-08-15 Pfizer USES OF CARBONITRIL DERIVATIVES, THEIR COMBINATION AND THEIR PHARMACEUTICAL COMPOSITION
CA3039855A1 (en) 2016-10-21 2018-04-26 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006087A1 (en) * 1994-08-22 1996-02-29 Smithkline Beecham Corporation Bicyclic compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2731217B1 (en) * 1995-03-03 1997-06-13 Roussel Uclaf NOVEL TRICYCLIC DERIVATIVES, THEIR PREPARATION, THEIR APPLICATION TO THE PREPARATION OF OPTICALLY ACTIVE OR RACEMIC COLCHICIN AND THIOCOLCHICIN AND ANALOGS OR DERIVATIVES AND INTERMEDIATES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006087A1 (en) * 1994-08-22 1996-02-29 Smithkline Beecham Corporation Bicyclic compounds

Also Published As

Publication number Publication date
NO312459B1 (en) 2002-05-13
BR9708231A (en) 1999-08-03
AP9801342A0 (en) 1998-09-30
AU2296697A (en) 1997-10-10
DE69707843T2 (en) 2002-05-16
EP0888292A1 (en) 1999-01-07
BG63569B1 (en) 2002-05-31
ATE207889T1 (en) 2001-11-15
NO984352D0 (en) 1998-09-18
KR20000064710A (en) 2000-11-06
SK124998A3 (en) 1999-08-06
LV12207A (en) 1999-01-20
SK282894B6 (en) 2003-01-09
BG102778A (en) 1999-05-31
JP4091983B2 (en) 2008-05-28
JP2000506879A (en) 2000-06-06
NZ331778A (en) 2000-02-28
GEP20012516B (en) 2001-08-27
DE69707843D1 (en) 2001-12-06
US6221907B1 (en) 2001-04-24
CA2249471A1 (en) 1997-09-25
EA199800837A1 (en) 1999-06-24
AU728852B2 (en) 2001-01-18
SI9720021A (en) 1999-04-30
LV12207B (en) 1999-03-20
NO984352L (en) 1998-11-19
DK0888292T3 (en) 2002-02-18
EA002271B1 (en) 2002-02-28
WO1997034865A1 (en) 1997-09-25
EP0888292B1 (en) 2001-10-31
EE9800317A (en) 1999-04-15

Similar Documents

Publication Publication Date Title
AP806A (en) Tricyclic compounds having activity specific for integrins, particularly avB3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same.
JP4077535B2 (en) Novel cycloalkyl derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
US6339082B1 (en) Tricyclic compounds, preparation method and said method intermediates, application as medicines and pharmaceutical compositions containing same
US6277845B1 (en) Hydrazono-benzazulene derivatives, pharmaceutical compositions and intermediates
US6459001B1 (en) Tricyclic compounds, their preparation process and the intermediates of this process, their use as medicaments and the pharmaceutical compositions containing them
MXPA98007529A (en) Triciclic compounds that have an activity against the integrines, especially in front of the integrina alfavbeta3, their preparation procedure and the intermediaries of this procedure, suaplication as medicines and the composition
US6362211B2 (en) Polycyclic indanylimidazoles with alpha2 adrenergic activity
HRP970163A2 (en) Novel tricyclic compounds, process for the preparation and intermediates thereof, the application thereof as medicaments ans pharmaceutical preparations containing them
AU2001258469A1 (en) New polycyclic indanylimidazoles with alpha2 adrenergic activity
US6500815B1 (en) Substituted 11.beta steroid derivatives, method for preparing same and intermediates of said method, use as medicine and compositions containing them